<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40005993</article-id><article-id pub-id-type="pmc">PMC11859726</article-id><article-id pub-id-type="doi">10.3390/ph18020179</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-18-00179</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>HDAC/&#x003c3;1R Dual-Ligand as a Targeted Melanoma Therapeutic</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Leotta</surname><given-names>Claudia Giovanna</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-pharmaceuticals-18-00179" ref-type="aff">1</xref><xref rid="af2-pharmaceuticals-18-00179" ref-type="aff">2</xref><xref rid="fn1-pharmaceuticals-18-00179" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6155-6702</contrib-id><name><surname>Barbaraci</surname><given-names>Carla</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af3-pharmaceuticals-18-00179" ref-type="aff">3</xref><xref rid="af4-pharmaceuticals-18-00179" ref-type="aff">4</xref><xref rid="fn1-pharmaceuticals-18-00179" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Fiorito</surname><given-names>Jole</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af5-pharmaceuticals-18-00179" ref-type="aff">5</xref><xref rid="af6-pharmaceuticals-18-00179" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4597-1025</contrib-id><name><surname>Coco</surname><given-names>Alessandro</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af3-pharmaceuticals-18-00179" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3332-993X</contrib-id><name><surname>di Giacomo</surname><given-names>Viviana</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af7-pharmaceuticals-18-00179" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4750-3479</contrib-id><name><surname>Amata</surname><given-names>Emanuele</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af3-pharmaceuticals-18-00179" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8728-8857</contrib-id><name><surname>Marrazzo</surname><given-names>Agostino</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af3-pharmaceuticals-18-00179" ref-type="aff">3</xref><xref rid="c1-pharmaceuticals-18-00179" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0698-8112</contrib-id><name><surname>Pitari</surname><given-names>Giovanni Mario</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-pharmaceuticals-18-00179" ref-type="aff">1</xref><xref rid="af2-pharmaceuticals-18-00179" ref-type="aff">2</xref><xref rid="c1-pharmaceuticals-18-00179" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Frija</surname><given-names>Lu&#x000ed;s M. T.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-18-00179"><label>1</label>Dream Factory Lab, Vera Salus Ricerca S.r.l., 96100 Siracusa, Italy</aff><aff id="af2-pharmaceuticals-18-00179"><label>2</label>J4Med Lab, Via Paolo Gaifami 9, 95126 Catania, Italy</aff><aff id="af3-pharmaceuticals-18-00179"><label>3</label>Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy</aff><aff id="af4-pharmaceuticals-18-00179"><label>4</label>Institut Catal&#x000e0; d&#x02019;Investigaci&#x000f3; Qu&#x000ed;mica (ICIQ), Avinguda dels Pa&#x000ef;sos Catalans 16, 43007 Tarragona, Spain</aff><aff id="af5-pharmaceuticals-18-00179"><label>5</label>Department of Biological and Chemical Sciences, New York Institute of Technology, Old Westbury, NY 11568, USA</aff><aff id="af6-pharmaceuticals-18-00179"><label>6</label>Department of Medicine, Columbia University, New York, NY 10032, USA</aff><aff id="af7-pharmaceuticals-18-00179"><label>7</label>Department of Pharmacy, University &#x0201c;G. d&#x02019;Annunzio&#x0201d;, Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy</aff><author-notes><corresp id="c1-pharmaceuticals-18-00179"><label>*</label>Correspondence: <email>marrazzo@unict.it</email> (A.M.); <email>giovanni.pitari@verasalusricerca.it</email> (G.M.P.)</corresp><fn id="fn1-pharmaceuticals-18-00179"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>28</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>18</volume><issue>2</issue><elocation-id>179</elocation-id><history><date date-type="received"><day>24</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>16</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background:</bold> In melanoma, multiligand drug strategies to disrupt cancer-associated epigenetic alterations and angiogenesis are particularly promising. Here, a novel dual-ligand with a single shared pharmacophore capable of simultaneously targeting histone deacetylases (HDACs) and sigma receptors (&#x003c3;Rs) was synthesized and subjected to phenotypic in vitro screening. <bold>Methods</bold>: Tumor cell proliferation and spreading were investigated using immortalized human cancer and normal cell lines. Angiogenesis was also evaluated in mouse endothelial cells using a tube formation assay. <bold>Results:</bold> The dual-ligand compound exhibited superior potency in suppressing both uveal and cutaneous melanoma cell viability compared to other cancer cell types or normal cells. Melanoma selectivity reflected inhibition of the HDAC-dependent epigenetic regulation of tumor proliferative kinetics, without involvement of &#x003c3;R signaling. In contrast, the bifunctional compound inhibited the formation of capillary-like structures, formed by endothelial cells, and tumor cell spreading through the specific regulation of &#x003c3;<sub>1</sub>R signaling, but not HDAC activity. <bold>Conclusions:</bold> Together, the present findings suggest that dual-targeted HDAC/&#x003c3;<sub>1</sub>R ligands might efficiently and simultaneously disrupt tumor growth, dissemination and angiogenesis in melanoma, a strategy amenable to future clinical applications in precision cancer treatment.</p></abstract><kwd-group><kwd>melanoma</kwd><kwd>dual-ligands</kwd><kwd>HDACi</kwd><kwd>&#x003c3;<sub>1</sub> receptor</kwd><kwd>cancer proliferation</kwd><kwd>angiogenesis</kwd><kwd>cell spreading</kwd></kwd-group><funding-group><award-group><funding-source>PO FESR</funding-source><award-id>G68I18000700007</award-id></award-group><award-group><funding-source>Italian MUR</funding-source><award-id>P20224L3NK</award-id><award-id>CUP E53D23015810001</award-id></award-group><award-group><funding-source>European Union&#x02014;Next Generation EU</funding-source><award-id>2022Z3BBPE_006</award-id></award-group><funding-statement>This research was funded by PO FESR 2014&#x02013;2020, Action 1.1.5, project titled &#x0201c;NuSTeO, Nuove Strategie Terapeutiche in Oftalmologia: Infezioni Batteriche, Virali e Microbiche&#x0201d;, CUP: G68I18000700007. Additional funding was provided by Italian MUR, PRIN&#x02013;2022 PNRR program (Project code: P20224L3NK, CUP E53D23015810001, PE5) funded by the European Union&#x02014;Next Generation EU, (D.D. 1409 del 14 September 2022 MUR) and PRIN-2022, Prot. 2022Z3BBPE_006, PE5.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-18-00179"><title>1. Introduction</title><p>Melanoma is a clinically aggressive cancer arising from the malignant transformation of melanocytes, pigment-producing cells resident at various tissue locations including the skin, mucosae, leptomeninges, eyes and inner ears [<xref rid="B1-pharmaceuticals-18-00179" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceuticals-18-00179" ref-type="bibr">2</xref>]. The main risk factor for malignant melanocyte transformation is exposure to ultraviolet radiation and the progressive accumulation of genetic mutations [<xref rid="B3-pharmaceuticals-18-00179" ref-type="bibr">3</xref>]. The two most common clinical presentations for melanoma are cutaneous melanoma (CM) and uveal melanoma (UM) [<xref rid="B4-pharmaceuticals-18-00179" ref-type="bibr">4</xref>]. Although CM represents less than 10% of all malignant skin tumors, it is the deadliest form of skin cancer, mainly due to its high metastatic potential [<xref rid="B4-pharmaceuticals-18-00179" ref-type="bibr">4</xref>]. As a consequence, patient survival rates at 5 years from diagnosis range from 98% to 16% for localized and metastatic CM, respectively [<xref rid="B5-pharmaceuticals-18-00179" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceuticals-18-00179" ref-type="bibr">6</xref>]. UM accounts instead for only 5% of all primary melanoma cases, and includes melanomas of the choroid, ciliary body and iris of the eye [<xref rid="B7-pharmaceuticals-18-00179" ref-type="bibr">7</xref>]. However, UM is the most common primary intraocular malignancy in adults [<xref rid="B7-pharmaceuticals-18-00179" ref-type="bibr">7</xref>], exhibiting a unique genetic mutational landscape and extremely aggressive behavior [<xref rid="B7-pharmaceuticals-18-00179" ref-type="bibr">7</xref>]. Thus, despite early diagnosis and treatment with conventional therapies, nearly 50% of all UM patients have poor outlooks and develop hepatic metastases within 1 year from diagnosis [<xref rid="B8-pharmaceuticals-18-00179" ref-type="bibr">8</xref>].</p><p>Epigenetic reprogramming via histone deacetylation has been identified as a crucial regulator of melanoma progression, driving the tumor mutation burden and the emergence of drug resistance [<xref rid="B9-pharmaceuticals-18-00179" ref-type="bibr">9</xref>]. In this regard, histone deacetylases (HDACs) are a class of enzymes that affect gene expression by removing acetyl groups from histone proteins, a process leading to chromatin condensation and transcriptional repression [<xref rid="B10-pharmaceuticals-18-00179" ref-type="bibr">10</xref>]. HDAC levels are often increased in malignant tumors, including CM and UM, and are inversely associated with favorable clinicopathological parameters and patient survival [<xref rid="B11-pharmaceuticals-18-00179" ref-type="bibr">11</xref>,<xref rid="B12-pharmaceuticals-18-00179" ref-type="bibr">12</xref>]. Moreover, experimental models of melanoma have unequivocally demonstrated HDAC involvement in the pathogenesis of the disease [<xref rid="B13-pharmaceuticals-18-00179" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceuticals-18-00179" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceuticals-18-00179" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceuticals-18-00179" ref-type="bibr">16</xref>]. Presumably, HDAC deregulation in cancer promotes alterations in coordinated transcriptional programs that control key cellular processes, such as cell proliferation, apoptosis, tumor metabolism and immunogenicity [<xref rid="B17-pharmaceuticals-18-00179" ref-type="bibr">17</xref>]. Noteworthy, a variety of HDAC inhibitors (HDACi) are being evaluated in multiple solid and hematologic malignancies, with promising results in CM and UM [<xref rid="B18-pharmaceuticals-18-00179" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceuticals-18-00179" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceuticals-18-00179" ref-type="bibr">20</xref>].</p><p>Tumor angiogenesis and invasion are critically permissive factors for metastatic progression in CM and UM [<xref rid="B21-pharmaceuticals-18-00179" ref-type="bibr">21</xref>]. UM cells secrete elevated levels of vascular endothelial growth factor (VEGF), which promotes cancer cell migration, endothelial activation and neovascularization in tumors [<xref rid="B21-pharmaceuticals-18-00179" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceuticals-18-00179" ref-type="bibr">22</xref>]. In addition, emerging targeted antiangiogenic therapies are proving utility in the potential management of patients with CM and UM. Among these, compounds targeting sigma receptors (&#x003c3;Rs) are attracting interest for their ability to specifically disrupt motility and angiogenesis-dependent processes in UM cells [<xref rid="B23-pharmaceuticals-18-00179" ref-type="bibr">23</xref>]. A class of unique proteins, &#x003c3;Rs are divided into two distinct subtypes: the &#x003c3;<sub>1</sub>R situated at the mitochondria-associated endoplasmic reticulum (ER) membrane, and the &#x003c3;<sub>2</sub>R in the ER-resident membrane [<xref rid="B24-pharmaceuticals-18-00179" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceuticals-18-00179" ref-type="bibr">25</xref>] encoded by the <italic toggle="yes">TMEM97</italic> gene [<xref rid="B26-pharmaceuticals-18-00179" ref-type="bibr">26</xref>]. Beyond their involvement in many physiological functions such as memory and brain plasticity, neurotransmission and pain [<xref rid="B24-pharmaceuticals-18-00179" ref-type="bibr">24</xref>], &#x003c3;Rs are upregulated in distinct cancer types and may contribute to tumor growth, invasion and angiogenesis [<xref rid="B27-pharmaceuticals-18-00179" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceuticals-18-00179" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceuticals-18-00179" ref-type="bibr">29</xref>].</p><p>Previously, dual-ligand prodrugs encompassing HDACi and &#x003c3;<sub>1</sub>R antagonist/&#x003c3;<sub>2</sub>R agonist functional profiles were developed [<xref rid="B30-pharmaceuticals-18-00179" ref-type="bibr">30</xref>], which provided potent antiproliferative and antimigratory effects in UM and VEGF-stimulated human retinal endothelial cells [<xref rid="B30-pharmaceuticals-18-00179" ref-type="bibr">30</xref>]. Subsequently, non-esterified multiligand drugs with simultaneous HDAC/&#x003c3;R signaling regulation were obtained and confirmed as a favorable antiproliferative pharmacology in various cancers [<xref rid="B23-pharmaceuticals-18-00179" ref-type="bibr">23</xref>]. In the present work, this latter series of hybrid dual-function ligands was expanded in the quest for a highly potent and selective anti-melanoma drug. Thus, employing an original design, a novel dual-ligand small molecule concurrently targeting HDAC enzymes and &#x003c3;<sub>1</sub>R was synthesized and subjected to functional characterization with respect to the proliferation and spreading of melanoma cells and endothelial-dependent angiogenic processes.</p></sec><sec sec-type="results" id="sec2-pharmaceuticals-18-00179"><title>2. Results</title><sec id="sec2dot1-pharmaceuticals-18-00179"><title>2.1. Design of the Dual-Target Anti-Melanoma Hybrid</title><p>To construct a novel HDAC/&#x003c3;R dual-ligand with meaningful anticancer and antiangiogenic actions, successful strategies of medicinal chemistry were employed, as earlier described [<xref rid="B23-pharmaceuticals-18-00179" ref-type="bibr">23</xref>,<xref rid="B30-pharmaceuticals-18-00179" ref-type="bibr">30</xref>]. Appropriate functional groups were selected to provide an original single pharmacophore capable of simultaneously targeting HDAC enzymes and &#x003c3;Rs and anticipated to display excellent binding affinities [<xref rid="B23-pharmaceuticals-18-00179" ref-type="bibr">23</xref>,<xref rid="B30-pharmaceuticals-18-00179" ref-type="bibr">30</xref>]. Specifically, the novel dual hybrid molecule (compound <bold>5c</bold>; original name, MRJF15) was conceived to exhibit three functionally distinct, chemical domains (<xref rid="pharmaceuticals-18-00179-f001" ref-type="fig">Figure 1</xref>): (a) a &#x003c3;R binding moiety, formed by the hydrophobic region I and the piperidine ring of the &#x003c3;<sub>1</sub>R antagonist/&#x003c3;<sub>2</sub>R agonist haloperidol with its conserved nitrogen atom, which plays a crucial role in &#x003c3;R binding; (b) a central hydrophobic linker, comprising the inner benzene of the HDACi LBH-589 (panobinostat); and (c) a zinc binding group (ZBG), represented by the hydroxamic acid group of panobinostat, responsible for chelating the metal Zn<sup>2+</sup> in the catalytic pocket of HDAC and inhibiting its activity [<xref rid="B31-pharmaceuticals-18-00179" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceuticals-18-00179" ref-type="bibr">32</xref>].</p><p>The structural configuration of the new dual-ligand <bold>5c</bold> afforded intentional, synergistic molecular features (<xref rid="pharmaceuticals-18-00179-f001" ref-type="fig">Figure 1</xref>). Thus, the &#x003c3;R binding moiety, with its hydrophobic portion, might alternatively serve as the capping region (CAP) for the HDACi moiety of the molecule, required for optimal enzymatic inhibition by sealing the access to the catalytic pocket of HDACs. Also, the central benzene could coincidentally fulfill the role of the hydrophobic region II for the &#x003c3;R ligand moiety of the dual-target hybrid [<xref rid="B33-pharmaceuticals-18-00179" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceuticals-18-00179" ref-type="bibr">34</xref>]. Importantly, the selected haloperidol portion should confer specific anti-melanoma and antiangiogenic properties by targeting &#x003c3;R signaling, mimicking its function in dual-target prodrugs [<xref rid="B30-pharmaceuticals-18-00179" ref-type="bibr">30</xref>]. Finally, the HDACi molecular end, formed by hydroxamic acid attached to the central benzene linker, should provide elevated tumor-selective antiproliferative pharmacology, as demonstrated in other HDAC/&#x003c3;R dual-function compounds [<xref rid="B23-pharmaceuticals-18-00179" ref-type="bibr">23</xref>].</p><p>In addition, the new dual-target hybrid is predicted to be a general HDACi but a selective &#x003c3;<sub>1</sub>R ligand [<xref rid="B23-pharmaceuticals-18-00179" ref-type="bibr">23</xref>]. These functional characteristics may shed light on the precise contribution of &#x003c3;R signaling in dual-ligand drug pharmacology. Fundamentally, the new dual-ligand hybrid displayed the critical structures of both the &#x003c3;R-binding haloperidol core and the zinc-chelating nucleus of an established HDACi (<xref rid="pharmaceuticals-18-00179-f001" ref-type="fig">Figure 1</xref>), rationally assembled in a compacted molecular configuration and providing a single pharmacophore for optimal therapeutic performance [<xref rid="B23-pharmaceuticals-18-00179" ref-type="bibr">23</xref>]. In this way, the design was aimed at obtaining a small molecule (386.88 Da) with improved ligand affinity, target selectivity and biological efficacy.</p></sec><sec id="sec2dot2-pharmaceuticals-18-00179"><title>2.2. Chemical Synthesis</title><p>The synthetic route for the preparation of the dual-ligand <bold>5c</bold>, an &#x003b1;,&#x003b2;-unsaturated hydroxamic acid derivative with a central benzene linker, involved four reaction steps (<xref rid="pharmaceuticals-18-00179-sch001" ref-type="fig">Scheme 1</xref>). In the first step, an esterification reaction was carried out between trans-4-formylcinnamic acid (compound <bold>1</bold>) and methyl iodide in N,N-dimethylformamide (DMF) to obtain (<italic toggle="yes">E</italic>)-3-(4-formylphenyl)methyl acrylate (compound <bold>2</bold>). Subsequently, a reductive amination reaction was performed between compound <bold>2</bold> and 4-(4-chlorophenyl)piperidin-4-ol in tetrahydrofuran (THF), in the presence of sodium triacetoxyborohydride [NaHB(OAc)<sub>3</sub>] and acetic acid, yielding compound <bold>3c</bold>. In the third step, the ester group of compound <bold>3c</bold> was hydrolyzed (in methanol) with 1 M lithium hydroxide (LiOH). Following hydrolysis, the carboxyl group was activated using ethyl chloroformate, in the presence of triethylamine in THF. Then, this activated intermediate underwent a nucleophilic reaction with O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (NH<sub>2</sub>OTHP) in THF, to produce compound <bold>4</bold>. Finally, the deprotection of the hydroxyamino group in compound <bold>4</bold> was achieved by hydrolysis with 0.6 N hydrochloric acid (HCl) aqueous solution, to obtain the final hybrid product <bold>5c</bold>.</p></sec><sec id="sec2dot3-pharmaceuticals-18-00179"><title>2.3. Molecular Pharmacology and Tumor Selectivity</title><p>Effective target engagements by the novel dual-function agent <bold>5c</bold> were assessed. First, &#x003c3;R binding affinities were determined by employing a radioligand binding assay [<xref rid="B23-pharmaceuticals-18-00179" ref-type="bibr">23</xref>,<xref rid="B30-pharmaceuticals-18-00179" ref-type="bibr">30</xref>]. Dual-targeted <bold>5c</bold> exhibited &#x0003e;100 fold higher affinity for &#x003c3;<sub>1</sub>R (Ki, 19.0 nM) than &#x003c3;<sub>2</sub>R (Ki, 2051.2 nM), suggesting the induction of selective &#x003c3;R signaling (<xref rid="pharmaceuticals-18-00179-t001" ref-type="table">Table 1</xref>) as for previous congeners [<xref rid="B23-pharmaceuticals-18-00179" ref-type="bibr">23</xref>]. Similarly, compound <bold>3c</bold>, the hydroxamic-null precursor of <bold>5c</bold> (<xref rid="pharmaceuticals-18-00179-sch001" ref-type="fig">Scheme 1</xref>) anticipated to lack HDACi activity, also behaved as a selective &#x003c3;<sub>1</sub>R ligand (<xref rid="pharmaceuticals-18-00179-t001" ref-type="table">Table 1</xref>) with superior binding affinities for &#x003c3;<sub>1</sub>R (Ki, 28.0 nM) than for &#x003c3;<sub>2</sub>R (Ki, 1330.0 nM). These binding behaviors differentiated <bold>3c</bold> and <bold>5c</bold> from their parental chemical scaffold haloperidol, which bound to both &#x003c3;<sub>1</sub>R and &#x003c3;<sub>2</sub>R with high affinities (<xref rid="pharmaceuticals-18-00179-t001" ref-type="table">Table 1</xref>) and resembled those of the selective &#x003c3;<sub>1</sub>R agonist pentazocine [<xref rid="B35-pharmaceuticals-18-00179" ref-type="bibr">35</xref>] (<xref rid="pharmaceuticals-18-00179-t001" ref-type="table">Table 1</xref>).</p><p>Next, the ability of <bold>5c</bold> to inhibit HDACs was investigated, employing various cancer cell lysates as biological sources of diverse HDAC enzymatic activities [<xref rid="B23-pharmaceuticals-18-00179" ref-type="bibr">23</xref>], including colon (HCT116), breast (MCF7), prostate (PC3) and gastric (AGS) carcinoma cells. First, dose&#x02013;response curves were generated for the HCT116 cell lysates (<xref rid="pharmaceuticals-18-00179-f002" ref-type="fig">Figure 2</xref>a), which demonstrated that <bold>5c</bold> reduces HDAC-dependent catalytic activity with a calculated 50% inhibitory concentration (IC<sub>50</sub>) of 14.6 nM. Importantly, HDACi activity by <bold>5c</bold> was profound (~80% inhibition with respect to the vehicle control) and of a similar extent to that of the positive control trichostatin A (<xref rid="app1-pharmaceuticals-18-00179" ref-type="app">Figure S1</xref>), a potent and non-selective HDAC inhibitor [<xref rid="B36-pharmaceuticals-18-00179" ref-type="bibr">36</xref>]. The HDAC inhibitory effects of <bold>5c</bold> were generalizable to other cancer cell types, with significant suppression of resident HDAC enzymatic activities compared to respective control conditions, which mirrored those of trichostatin A (<xref rid="app1-pharmaceuticals-18-00179" ref-type="app">Figure S1</xref>). Together, the molecular pharmacology studies of receptor engagements indicated that <bold>5c</bold> may signal as a dual-target ligand with selective &#x003c3;<sub>1</sub>R, but general HDACi actions.</p><p>To establish the anti-melanoma selective effects of the novel HDAC/&#x003c3;<sub>1</sub>R hybrid, complete antiproliferative dose&#x02013;response curves were generated by employing two in vitro human models, the UM 92-1 cells and normal lung fibroblasts MRC-5 (<xref rid="pharmaceuticals-18-00179-f002" ref-type="fig">Figure 2</xref>b). The UM 92-1 model was intentionally chosen for these studies because 92-1 cells express all the molecular targets of interest, including HDAC proteins and both &#x003c3;<sub>1</sub>R and &#x003c3;<sub>2</sub>R [<xref rid="B30-pharmaceuticals-18-00179" ref-type="bibr">30</xref>,<xref rid="B37-pharmaceuticals-18-00179" ref-type="bibr">37</xref>]. Moreover, they exhibit sensitivity to anticancer actions by dual-target HDAC/&#x003c3;R prodrugs [<xref rid="B30-pharmaceuticals-18-00179" ref-type="bibr">30</xref>]. The lung fibroblasts MRC-5 were in turn interrogated as an experimental surrogate of normal systemic tissues, to ascertain in vitro safety. Of relevance, <bold>5c</bold> appropriately discriminated between tumor and normal cells, with antiproliferative sigmoidal curves shifted to the left in 92-1 cells, compared to MRC-5 cells (<xref rid="pharmaceuticals-18-00179-f002" ref-type="fig">Figure 2</xref>b). Estimates of antiproliferative IC<sub>50</sub> confirmed that this hybrid exhibited significantly superior (~5 fold) potency in UM cells, compared to normal lung fibroblasts (<xref rid="pharmaceuticals-18-00179-t002" ref-type="table">Table 2</xref>). This latter finding is important because it suggests that <bold>5c</bold> possesses favorable therapeutic profiles, reflecting selective anti-melanoma actions, in the context of safer behaviors in normal cells (<xref rid="pharmaceuticals-18-00179-t002" ref-type="table">Table 2</xref>).</p></sec><sec id="sec2dot4-pharmaceuticals-18-00179"><title>2.4. Cancer Specificity and Antiproliferative Signaling in Melanoma Cells</title><p>The tumor specificity of the test compound was investigated by employing immortalized human cells from four different cancers (CM A375, lung A549, renal 786-O and colorectal T84) and normal skin fibroblast WS1 (<xref rid="pharmaceuticals-18-00179-f002" ref-type="fig">Figure 2</xref>c). Dual-ligand hybrid <bold>5c</bold> efficiently and selectively reduced proliferation in three additional human cancers (CM, lung and renal adenocarcinomas) compared to normal skin fibroblasts, as indicated by the ~8&#x02013;10 fold shift to the left in correspondent antiproliferative dose&#x02013;response curves (<xref rid="pharmaceuticals-18-00179-f002" ref-type="fig">Figure 2</xref>c). In contrast, colon cancer T84 cells were resistant to <bold>5c</bold> antitumor actions (<xref rid="pharmaceuticals-18-00179-f002" ref-type="fig">Figure 2</xref>c). IC<sub>50</sub> calculations confirmed that compound <bold>5c</bold> exhibited higher antiproliferative potencies in melanoma cells (both UM and CM), compared to other normal or cancer cell types (<xref rid="pharmaceuticals-18-00179-t002" ref-type="table">Table 2</xref>). Accordingly, a heat map representation of IC<sub>50</sub> values from all cancer cells demonstrated a melanoma-specific sensitivity to <bold>5c</bold> antiproliferation, with UM 92-1 and CM A375 cells ranking as the first and second most suppressed tumors, respectively, by the multiligand hybrid (<xref rid="pharmaceuticals-18-00179-f002" ref-type="fig">Figure 2</xref>d).</p><p>Importantly, melanoma-specific antiproliferation by <bold>5c</bold> reflected HDAC targeting and suppression of dependent epigenetic regulations, as demonstrated by the loss of activity upon disruption of the HDACi-enabling hydroxamic group (with precursor compound <bold>3c</bold>; <xref rid="pharmaceuticals-18-00179-sch001" ref-type="fig">Scheme 1</xref> and <xref rid="pharmaceuticals-18-00179-f003" ref-type="fig">Figure 3</xref>). In contrast, exposure of UM (<xref rid="pharmaceuticals-18-00179-f003" ref-type="fig">Figure 3</xref>a) and A375 (<xref rid="pharmaceuticals-18-00179-f003" ref-type="fig">Figure 3</xref>b) cells to the &#x003c3;<sub>1</sub>R agonist pentazocine or the &#x003c3;<sub>2</sub>R antagonist AC927 [<xref rid="B38-pharmaceuticals-18-00179" ref-type="bibr">38</xref>] did not alter their proliferative kinetics, nor did it perturb <bold>5c</bold>&#x02019;s antiproliferative actions. Together, these data indicate that HDAC, but not &#x003c3;R, is the main pharmacological target for <bold>5c</bold>-mediated antiproliferation in human melanoma cells.</p></sec><sec id="sec2dot5-pharmaceuticals-18-00179"><title>2.5. Effects on Endothelial-Dependent Angiogenic Processes</title><p>The ability of the dual-function hybrid <bold>5c</bold> to affect endothelial-driven neoangiogenesis was explored using the tube formation assay with mouse endothelial C166 cells (<xref rid="pharmaceuticals-18-00179-f004" ref-type="fig">Figure 4</xref>). To focus on the motility and phenotypic organization of capillary-like structures (<xref rid="pharmaceuticals-18-00179-f004" ref-type="fig">Figure 4</xref>a) [<xref rid="B39-pharmaceuticals-18-00179" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceuticals-18-00179" ref-type="bibr">40</xref>] away from the mechanistic contributions of cell proliferation, short observational periods (3 h) were selected upon C166 cell seeding onto basement membrane-like Matrigel and VEGF-A-stimulation [<xref rid="B39-pharmaceuticals-18-00179" ref-type="bibr">39</xref>]. As expected, VEGF-A activated the endothelial C166 cells and promoted the formation of vasculature-like networks to a greater degree than the vehicle control (<xref rid="pharmaceuticals-18-00179-f004" ref-type="fig">Figure 4</xref>a,b). Also, the HDAC/&#x003c3;Rs bifunctional prodrug (S)-(-)-MRJF22 [(-)-1], used as the positive control [<xref rid="B30-pharmaceuticals-18-00179" ref-type="bibr">30</xref>], significantly inhibited angiogenesis by VEGF-A in these cells (<xref rid="pharmaceuticals-18-00179-f004" ref-type="fig">Figure 4</xref>a,b). Treatment with <bold>5c</bold> at antiproliferative concentrations (30 nM; <xref rid="pharmaceuticals-18-00179-f003" ref-type="fig">Figure 3</xref>) was without effects on VEGF-A-stimulated angiogenesis (<xref rid="pharmaceuticals-18-00179-f004" ref-type="fig">Figure 4</xref>b). In contrast, C166 exposure to <bold>5c</bold> at 5 &#x000b5;M, a concentration level capable of inducing &#x003c3;R-dependent antiangiogenesis [<xref rid="B30-pharmaceuticals-18-00179" ref-type="bibr">30</xref>], abrogated the ability of VEGF-A to induce neovascular networks (<xref rid="pharmaceuticals-18-00179-f004" ref-type="fig">Figure 4</xref>a), with significant suppression of quantitative angiogenic parameters including tube lengths, mesh areas and node numbers (<xref rid="pharmaceuticals-18-00179-f004" ref-type="fig">Figure 4</xref>b). Of relevance, the hydroxamic-null compound <bold>3c</bold> mimicked the effects of <bold>5c</bold> on endothelial-dependent angiogenesis (<xref rid="pharmaceuticals-18-00179-f004" ref-type="fig">Figure 4</xref>b), demonstrating that HDACi is not involved in the disruption of VEGF-induced microvascular organizations by the novel dual-target hybrid.</p><p>Application of the &#x003c3;<sub>1</sub>R agonist pentazocine or the &#x003c3;<sub>2</sub>R antagonist AC927 inhibited the ability of <bold>5c</bold>, <bold>3c</bold> and (-)-1 to suppress the proangiogenic phenotype of C166 cells, although with different degrees of efficiency with respect to each ligand and the precise angiogenic parameter quantified (<xref rid="app1-pharmaceuticals-18-00179" ref-type="app">Figure S2</xref>). A comprehensive examination of <bold>5c</bold>-dependent antiangiogenesis (<xref rid="pharmaceuticals-18-00179-f005" ref-type="fig">Figure 5</xref>a), achieved by combining all parameters examined in one score, revealed that pentazocine completely prevented <bold>5c</bold>&#x02019;s effects on vascular tube formations (<xref rid="pharmaceuticals-18-00179-f005" ref-type="fig">Figure 5</xref>b). AC927 also inhibited <bold>5c</bold>&#x02019;s actions on angiogenesis, but to a significantly lesser extent than pentazocine (<xref rid="pharmaceuticals-18-00179-f005" ref-type="fig">Figure 5</xref>b). In contrast, inhibitory activities of VEGF-A-stimulated angiogenesis by (-)-1, a signaling ligand of both &#x003c3;<sub>1</sub>R and &#x003c3;<sub>2</sub>R [<xref rid="B30-pharmaceuticals-18-00179" ref-type="bibr">30</xref>], were partially and equally blocked by co-incubations with pentazocine or AC927 (<xref rid="pharmaceuticals-18-00179-f005" ref-type="fig">Figure 5</xref>). All together, these observations suggest that the HDAC/&#x003c3;<sub>1</sub>R dual-target <bold>5c</bold> inhibits VEGF-A-stimulated vascular morphogenesis in endothelial C166 cells by acting as a selective &#x003c3;<sub>1</sub>R antagonist, but without the involvement of HDAC-dependent pathways.</p></sec><sec id="sec2dot6-pharmaceuticals-18-00179"><title>2.6. Receptor Signaling in Melanoma Cell Spreading</title><p>In solid tumors, changes in cancer cell shape (spreading) underlies migration, invasion and metastasis to distant organs [<xref rid="B41-pharmaceuticals-18-00179" ref-type="bibr">41</xref>]. The impact of the HDAC/&#x003c3;1R dual-ligand <bold>5c</bold> on locomotory organelle formation (lamellipodia, filopodia) in melanoma cells was investigated with the tumor cell spreading assay [<xref rid="B42-pharmaceuticals-18-00179" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceuticals-18-00179" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceuticals-18-00179" ref-type="bibr">44</xref>]. Quantification of the fraction of UM 92-1 cells extending membrane protrusions revealed that short <bold>5c</bold> exposures (1 h) provoked a shrinkage of this migratory cell population, with a correspondent expansion of cells with rounded morphology (<xref rid="app1-pharmaceuticals-18-00179" ref-type="app">Table S1</xref>). In contrast to antiangiogenic effects (<xref rid="pharmaceuticals-18-00179-f004" ref-type="fig">Figure 4</xref>), significant inhibition of the invasive cell shape by <bold>5c</bold> was already apparent at low concentrations (100 nM; <xref rid="pharmaceuticals-18-00179-f006" ref-type="fig">Figure 6</xref>), coincident with those eliciting anti-melanoma proliferation (<xref rid="pharmaceuticals-18-00179-f003" ref-type="fig">Figure 3</xref>). The HDACi-null analog <bold>3c</bold> also significantly suppressed membrane protrusion-driven 92-1 cell spreading, with nearly identical efficacy and potency as <bold>5c</bold> (<xref rid="pharmaceuticals-18-00179-f006" ref-type="fig">Figure 6</xref>). Although with similar efficacy, the reference HDAC/&#x003c3;R multiligand prodrug (-)-1, which does not discriminate between &#x003c3;<sub>1</sub>R and &#x003c3;<sub>2</sub>R [<xref rid="B30-pharmaceuticals-18-00179" ref-type="bibr">30</xref>], reduced UM cell spreading with seemingly higher potencies (<xref rid="pharmaceuticals-18-00179-f006" ref-type="fig">Figure 6</xref>).</p><p>To establish the role of &#x003c3;<sub>1</sub>R as the downstream molecular target for the dual-function hybrid <bold>5c</bold>, locomotory-driven cell spreading was then examined in human breast cancer MCF7 cells, which exhibit low levels of endogenous &#x003c3;<sub>1</sub>R protein and silenced &#x003c3;<sub>1</sub>R-dependent biological pathways [<xref rid="B45-pharmaceuticals-18-00179" ref-type="bibr">45</xref>]. Treatment with <bold>5c</bold> failed to suppress tumor cell spreading in MCF7 cells (<xref rid="pharmaceuticals-18-00179-f006" ref-type="fig">Figure 6</xref>). Accordingly, the HDACi-null analog <bold>3c</bold> and the reference prodrug (-)-1 were unable to significantly inhibit MCF7 cell spreading (<xref rid="pharmaceuticals-18-00179-f006" ref-type="fig">Figure 6</xref>). Together, these findings support the hypothesis that HDAC/&#x003c3;<sub>1</sub>R dual-target <bold>5c</bold> disrupts locomotory organelle formation in melanoma cells by selectively targeting &#x003c3;<sub>1</sub>R signaling pathways, without the involvement of HDAC regulation.</p></sec></sec><sec sec-type="discussion" id="sec3-pharmaceuticals-18-00179"><title>3. Discussion</title><p>Compounds with multi-target pharmacology are emerging as promising small molecules for the safer, more efficacious therapeutic management of multifactorial diseases such as cancer [<xref rid="B23-pharmaceuticals-18-00179" ref-type="bibr">23</xref>,<xref rid="B30-pharmaceuticals-18-00179" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceuticals-18-00179" ref-type="bibr">31</xref>]. In this context, compared to multitherapy with distinct drugs, the simultaneous regulation of different molecular targets, endowed by the dual-ligand strategy, should enable low-dose exposures and improve patient compliance by reducing off-target effects [<xref rid="B31-pharmaceuticals-18-00179" ref-type="bibr">31</xref>]. Indeed, dual-ligands are superior therapeutics anticipated to target distinct biological sites of action in the same tumor cell, thereby maximizing treatment responses. Moreover, this innovative synthetic design is suited to enhance drug therapeutic potentials further, exploiting the synergistic opportunities offered by simultaneously targeting distinct pathways while minimizing the risk of target-based drug resistance [<xref rid="B31-pharmaceuticals-18-00179" ref-type="bibr">31</xref>].</p><p>Dual-target drugs could be particularly useful in melanoma, a disease with poor prognosis and high treatment failure rates [<xref rid="B1-pharmaceuticals-18-00179" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceuticals-18-00179" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceuticals-18-00179" ref-type="bibr">3</xref>]. Accordingly, HDAC/&#x003c3;R dual-ligand prodrugs reduced UM cell proliferation and motility while concurrently opposing angiogenic processes stimulated by VEGF [<xref rid="B30-pharmaceuticals-18-00179" ref-type="bibr">30</xref>]. In the present study, a novel dual-function HDAC/&#x003c3;R hybrid was synthesized by employing a pharmacophore fusion approach, wherein the &#x003c3;R ligand part of the molecule was directly attached to the central hydrophobic linker of the selected HDACi moiety (<xref rid="pharmaceuticals-18-00179-f001" ref-type="fig">Figure 1</xref>). Importantly, the distinct structural components of the parental ligands simultaneously provided reciprocal permissive domains to the dual-target pharmacophore, with the HDACi&#x02019;s hydrophobic linker acting as the hydrophobic region II for the &#x003c3;R ligand, and the distal hydrophobic end of the &#x003c3;R ligand as the CAP portion for HDACi (<xref rid="pharmaceuticals-18-00179-f001" ref-type="fig">Figure 1</xref>). In this way, the key functional groups of the precursor drugs contributed to forming a single pharmacophore, simultaneously fitting HDAC and &#x003c3;R whilst maintaining excellent binding interactions.</p><p>Importantly, the newly developed dual hybrid <bold>5c</bold> induced potent antiproliferative actions in cancers, which were tumor-selective and specific to UM and CM cells (<xref rid="pharmaceuticals-18-00179-t002" ref-type="table">Table 2</xref>). The melanoma selectivity reflected the inhibition of HDAC-dependent epigenetic regulation of proliferative kinetics, without the involvement of &#x003c3;R signaling, as demonstrated by the lack of inhibitory effects using the hydroxamic-null precursor <bold>3c</bold> (<xref rid="pharmaceuticals-18-00179-f003" ref-type="fig">Figure 3</xref>). Apart from the essential role of ZBG, though, it is conceivable to speculate that additional structural components of the hybrid <bold>5c</bold> strengthen its antiproliferative activity. Among these, the hydrophobic benzene of the central linker (<xref rid="pharmaceuticals-18-00179-f001" ref-type="fig">Figure 1</xref>) was previously selected as a biologically optimal molecular module, conferring potent anticancer activities on HDAC/&#x003c3;R dual-ligands [<xref rid="B23-pharmaceuticals-18-00179" ref-type="bibr">23</xref>]. Moreover, the CAP region for HDACi, covered in the novel hybrid by its &#x003c3;R moiety (<xref rid="pharmaceuticals-18-00179-f001" ref-type="fig">Figure 1</xref>), seals the gate of the catalytic pocket and is instrumental in elevated HDAC inhibition.</p><p>HDACs comprise an important family of 18 isozymes that can induce profound epigenetic modifications in cells and are being pursued as drug targets for many types of disorders [<xref rid="B9-pharmaceuticals-18-00179" ref-type="bibr">9</xref>]. In cancers, these enzymes regulate the expression and activity of numerous proteins involved in tumor initiation and progression [<xref rid="B46-pharmaceuticals-18-00179" ref-type="bibr">46</xref>]. By removing acetyl groups from histones, HDACs create a non-permissive chromatin conformation that prevents the transcription of specific genes. However, in addition to histones, HDACs can bind to and deacetylate a variety of other protein targets, including transcription factors and other abundant cellular proteins implicated in the control of cell growth, differentiation and apoptosis [<xref rid="B9-pharmaceuticals-18-00179" ref-type="bibr">9</xref>]. As a result, HDACis have recently emerged as promising cancer therapeutics, including in UM and CM [<xref rid="B46-pharmaceuticals-18-00179" ref-type="bibr">46</xref>]. Since the dual-ligand <bold>5c</bold> behaves as a non-selective HDACi in various tumor cells (<xref rid="app1-pharmaceuticals-18-00179" ref-type="app">Figure S1</xref>), it is predicated that its role as an anticancer agent could be generalized to other cancers, beyond its specific antiproliferative effects in melanomas.</p><p>Of note, the dual hybrid <bold>5c</bold> provided a novel selective &#x003c3;<sub>1</sub>R ligand, expanding the class of similar dual-ligand congeners [<xref rid="B23-pharmaceuticals-18-00179" ref-type="bibr">23</xref>]. Indeed, <bold>5c</bold> exhibited different &#x003c3;R binding affinities than its chemical scaffold haloperidol, with similar &#x003c3;<sub>1</sub>R affinity but disrupted &#x003c3;<sub>2</sub>R binding ability, effects shared by the ester precursor <bold>3c</bold> (<xref rid="pharmaceuticals-18-00179-t001" ref-type="table">Table 1</xref>). These original functional outcomes probably reflect the substantial pharmacophore remodeling of the novel dual-ligand compound (and its hydroxamic-null precursor), which comprises a differentially rearranged hydrophobic region II (<xref rid="pharmaceuticals-18-00179-f001" ref-type="fig">Figure 1</xref>). Moreover, <bold>5c</bold> functioned as a selective &#x003c3;<sub>1</sub>R antagonist (<xref rid="pharmaceuticals-18-00179-f005" ref-type="fig">Figure 5</xref>) whose biological activity was antagonized by pentazocine, a putative &#x003c3;<sub>1</sub>R agonist (<xref rid="pharmaceuticals-18-00179-t001" ref-type="table">Table 1</xref>).</p><p>The &#x003c3;<sub>1</sub>R is a unique integral membrane chaperone operating in mitochondria-associated ER domains [<xref rid="B25-pharmaceuticals-18-00179" ref-type="bibr">25</xref>,<xref rid="B27-pharmaceuticals-18-00179" ref-type="bibr">27</xref>]. Acting as a scaffolding protein that allosterically modulates the activity of its associated proteins, &#x003c3;<sub>1</sub>R is increasingly regarded as a key regulatory signaling receptor implicated in many biological processes [<xref rid="B47-pharmaceuticals-18-00179" ref-type="bibr">47</xref>]. In cancer, &#x003c3;<sub>1</sub>R ligands inhibited tumor migration, proliferation and survival [<xref rid="B47-pharmaceuticals-18-00179" ref-type="bibr">47</xref>]. Furthermore, &#x003c3;<sub>1</sub>R has been demonstrated to suppress tumor growth, alleviate cancer-associated pain and exert immunomodulation [<xref rid="B30-pharmaceuticals-18-00179" ref-type="bibr">30</xref>]. Here, the bifunctional <bold>5c</bold> compound inhibited VEGF-stimulated capillary morphogenesis by endothelial cells, through the specific regulation of &#x003c3;<sub>1</sub>R signaling, but not HDAC (<xref rid="pharmaceuticals-18-00179-f005" ref-type="fig">Figure 5</xref>). These results are in agreement with the modulation of angiogenesis by &#x003c3;<sub>1</sub>R in various cell models [<xref rid="B46-pharmaceuticals-18-00179" ref-type="bibr">46</xref>] and support the utility of targeting this receptor to oppose hematogenous tumor cell dissemination.</p><p>Selective &#x003c3;<sub>1</sub>R targeting with the dual-function hybrid <bold>5c</bold> also disrupted invasive locomotory organelle formation in melanoma cells (<xref rid="pharmaceuticals-18-00179-f006" ref-type="fig">Figure 6</xref>). In this context, invading tumor cells form membrane protrusions (e.g., lamellipodia, filopodia) to spread and migrate into neighboring tissues by extending their leading edges along the direction of the invasive front [<xref rid="B43-pharmaceuticals-18-00179" ref-type="bibr">43</xref>,<xref rid="B45-pharmaceuticals-18-00179" ref-type="bibr">45</xref>]. Thus, the inhibition of &#x003c3;<sub>1</sub>R functions through pharmacological antagonism could afford the dual-ligand hybrid significant antimetastatic potential in melanoma. Accordingly, the colon cancer cell shape which promotes migration and invasion was suppressed by &#x003c3;<sub>1</sub>R signaling through the human voltage-dependent K<sup>+</sup> channel human ether-&#x000e0;-go-go-related gene [<xref rid="B48-pharmaceuticals-18-00179" ref-type="bibr">48</xref>]. Moreover, &#x003c3;<sub>1</sub>R is often upregulated in tumors [<xref rid="B49-pharmaceuticals-18-00179" ref-type="bibr">49</xref>,<xref rid="B50-pharmaceuticals-18-00179" ref-type="bibr">50</xref>], and its expression potentiated invasive cancer behavior and angiogenesis in vivo, resulting in poor survival [<xref rid="B48-pharmaceuticals-18-00179" ref-type="bibr">48</xref>].</p><p>Taken collectively, the present findings suggest that dual-targeted HDAC/&#x003c3;<sub>1</sub>R ligands could represent a novel paradigm for melanoma therapeutics, being versatile and highly potent. Indeed, they are predicted to efficiently and simultaneously oppose many cancer-permissive pathogenetic programs in melanoma, including tumor proliferation, migration, invasion, angiogenesis and metastasis.</p></sec><sec id="sec4-pharmaceuticals-18-00179"><title>4. Materials and Methods</title><sec id="sec4dot1-pharmaceuticals-18-00179"><title>4.1. Chemistry</title><sec id="sec4dot1dot1-pharmaceuticals-18-00179"><title>4.1.1. General Procedure</title><p>Required chemicals were obtained from Merck (Darmstadt, Germany) or Fluorochem (Derbyshire, UK). All reagents and chemicals were processed, and reactions performed as previously detailed [<xref rid="B30-pharmaceuticals-18-00179" ref-type="bibr">30</xref>]. Flash chromatography purification was done on Merck silica gels 60 (230&#x02212;400 mesh) and nuclear magnetic resonance spectra (<sup>1</sup>H NMR and <sup>13</sup>C NMR recorded at 500 MHz) were acquired with Varian INOVA spectrometers, using CDCl<sub>3</sub>, CD<sub>3</sub>OD and DMSO-<italic toggle="yes">d</italic><sub>6</sub> with 0.03% of TMS as the internal standard (<xref rid="app1-pharmaceuticals-18-00179" ref-type="app">Figures S3 and S4</xref>) [<xref rid="B30-pharmaceuticals-18-00179" ref-type="bibr">30</xref>]. High Resolution Mass Spectrometry (HRMS) was conducted using Q-Exactive with ESI source (Thermo Scientific, Waltham, MA, USA). MS full scan acquisitions were performed in positive ion mode, in the m/z range 150.0&#x02013;800.0. The HCD gas on fragmentation method was used, settled in enhanced resolution, with a maximum injection time of 50 ns (<xref rid="app1-pharmaceuticals-18-00179" ref-type="app">Figures S5 and S6</xref>).</p></sec><sec id="sec4dot1dot2-pharmaceuticals-18-00179"><title>4.1.2. Synthesis and Product Characterization</title><p>Methyl-(2E)-3-(4-formylphenyl)prop-2-enoate (<bold>2</bold>). The synthesis of intermediary <bold>2</bold> was performed as described in previous studies [<xref rid="B23-pharmaceuticals-18-00179" ref-type="bibr">23</xref>]. The obtained solid product (4.6 g) exhibited a yield of 85.4%. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>): &#x003b4; 3.80 (s, 3H), 6.53 (d, J = 16.0 Hz, 1H), 7.63&#x02013;7.90 (m, 5H), 10.01(s, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>): 53.41, 116.80, 128.52, 129.53, 134.90, 138.15, 142.28, 163.69, 191.22.</p><p>Reductive amination. Compound <bold>2</bold> (7.3 mmol) was added (dropwise; RT) to an anhydrous tetrahydrofuran (THF) solution of 4-(4-chlorophenyl)piperidin-4-ol (7.3 mmol) under a nitrogen atmosphere. After addition of AcOH (7.3 mmol), the reaction mixture was stirred (30 min) and added dropwise to a NaBH(OAc)<sub>3</sub> solution (10.9 mmol) in 1.85 mL of anhydrous THF at RT in a nitrogen atmosphere. The reaction mixture was stirred overnight at RT. Subsequently, a saturated solution of NaHCO<sub>3</sub> was added, and the aqueous phase was repeatedly extracted with CHCl<sub>3</sub>. The combined organic phases were dried with Na<sub>2</sub>SO<sub>4</sub> anhydrous, filtered, and evaporated under vacuum. The crude was purified by MPLC using EtOAc as the eluent to obtain intermediate <bold>3</bold> (compound <bold>3c</bold>):</p><p>Metil-(E)-3-(4-{[4-(4-clorofenil)-4-idrossipiperidin-1-il]methyl}phenyl)acrylate (<bold>3</bold>, compound <bold>3c</bold>). White solid 4.78 g (yield 73%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) &#x003b4; 7.85&#x02013;7.60 (d, 1H, J = 15.0 Hz), 7.49&#x02013;7.29 (m, 8H), 6.425 (d, 1H, J = 15.0 Hz), 3.80 (s, 3H), 3,58 (s, 2H), 2.77&#x02013;2.75 (m, 2H), 2.49&#x02013;2.44 (m, 2H), 2.15&#x02013;2.09 (m, 2H), 1.72&#x02013;1.65 (m, 2H). <sup>13</sup>C NMR (500 MHz, CDCl<sub>3</sub>) &#x003b4; 167.51, 146,84, 144.63, 133.24, 132.76, 129.56, 128.38, 128.04, 126.10, 117.35, 71.02, 62.75, 51.69, 49.36, 38.43. HRMS (ESI, m/z) calcd for [C<sub>22</sub>H<sub>25</sub>ClNO<sub>3</sub>]<sup>+</sup> (M + H)<sup>+</sup> 386.152, found. 386.144.</p><p>Synthesis of the hydroxyamide. An aqueous solution of LiOH 1 M (2 mmol) was added dropwise (at 50 &#x000b0;C) to a MeOH solution of intermediate <bold>3</bold> (compound <bold>3c</bold>; 1 mmol), and the reaction mixture was stirred overnight. After solvent evaporation (in vacuum), residues were dissolved in THF/DMF (1:1) and supplemented first with TEA (2 mmol), and then with an ethyl chloroformate solution (4 mmol) in THF (added dropwise at 0 &#x000b0;C). Following 3 h stirring, O-(tetrahydro-2H-pyran-2-yl)-hydroxylamine (5 mmol) was added under nitrogen at RT, and the reaction stirred overnight. The resulting residue was washed with a saturated solution of NaHCO<sub>3</sub>, and the aqueous phase extracted with CHCl<sub>3</sub>. The combined organic phases were dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The crude was purified by MPLC to obtain the intermediate <bold>4</bold>:</p><p>(E)-3-(4-{[4-(4-clorofenil)-4-idrossipiperidin-1-il]metil}fenil)-N-(tetrahydro-2H-pyran-2-yl-oxy) acrylamide (<bold>4</bold>). White solid 0.310 g (yield 65%). <sup>1</sup>H NMR (DMSO-d<sub>6</sub>) &#x003b4; 11.20 (s, 1H), 7.54&#x02013;7.34 (m, 9H), 6.49 (d, 1H), 4.91&#x02013;4.89 (m, 2H), 3.98&#x02013;3.96 (m, 1H), 3.15 (s, 2H), 2.60&#x02013;2.56 (m, 2H), 2.45&#x02013;2.43 (m, 2H), 189&#x02013;193 (m, 2H), 1.78&#x02013;1.62 (m, 2H), 1.58&#x02013;1.54 (m, 6H). <sup>13</sup>C NMR (DMSO-d<sub>6</sub>) &#x003b4; 165.55, 162.57, 149.03, 140.71, 139.25, 133.30, 130.75, 129.34, 127.77, 127.43, 126.80, 118.15, 100.98, 69.36, 61.85, 61.35, 48.86, 37.81, 27.77, 24.63, 18.26.</p><p>Then, a solution of HCl 1.25 M in EtOH was added (dropwise at 0 &#x000b0;C) to an EtOH solution of intermediate <bold>4</bold>, and the reaction was stirred for 24 h (at RT). After solvent evaporation (in vacuum), the residue was dissolved in EtOH and precipitated with Et<sub>2</sub>O to obtain <bold>5</bold> (compound <bold>5c</bold>):</p><p>(E)-4-(4-chlorophenyl)-4-hydroxy-1-{4-[3-(hydroxyamino)-3-oxoprop-1-en-1-yl]benzyl}piperidin-1-ium chloride (<bold>5</bold>, compound <bold>5c</bold>). White solid 72 mg (yield 88%). <sup>1</sup>H NMR (DMSO-<italic toggle="yes">d</italic><sub>6</sub>) &#x003b4; 11.24 (broad s, 1H), 7.73&#x02013;7.41 (m, 9H), 6.55 (d, 1H, J = 15 Hz), 4.37&#x02013;4.36 (m, 2H), 3.26&#x02013;3.20 (m, 4H), 2.50 (s, 2H), 1.75&#x02013;1.78 (m, 2H). <sup>13</sup>C NMR (DMSO-<italic toggle="yes">d</italic><sub>6</sub>) &#x003b4; 162.36, 146.95, 137.34, 135.84, 132.02, 131.242, 130.86, 128.00, 127.62, 126.55, 120.32, 67.94, 58.22, 47.68, 34.65. Anal. calcd. for C<sub>21</sub>H<sub>23</sub>ClN<sub>2</sub>O<sub>3</sub>&#x02e31;HCl: C, 65.20; H, 7.24; N, 5.99; Found: C, 65.34; H, 6.98; N, 6.17. HRMS (ESI, m/z) calcd for [C<sub>21</sub>H<sub>24</sub>ClN<sub>2</sub>O<sub>3</sub>]<sup>+</sup> (M + H)<sup>+</sup> 387.148, found. 387.139.</p></sec></sec><sec id="sec4dot2-pharmaceuticals-18-00179"><title>4.2. Cell Cultures and Reagents</title><p>Unless otherwise specified, cell lines were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA). Human UM cell line 92-1 was maintained at 37 &#x000b0;C (5% CO<sub>2</sub>) in RPMI-1640 medium, containing 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 units/mL penicillin and 100 &#x000b5;g/mL streptomycin. Human renal adenocarcinoma cell line 786-O (ATCC<sup>&#x000ae;</sup> CRL-1932&#x02122;) was cultured in RPMI with 10% FBS. Human cutaneous melanoma cells A375 (ATCC<sup>&#x000ae;</sup> CRL-1619&#x02122;), human lung adenocarcinoma A549 (ATCC<sup>&#x000ae;</sup> CCL-185&#x02122;) and mouse endothelial cell C166 (ATCC<sup>&#x000ae;</sup> CRL-2581&#x02122;) were cultured in Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM) with 10% FBS, whereas human skin fibroblast WS1 (ATCC<sup>&#x000ae;</sup> CRL-1502&#x02122;) and human lung fibroblast MRC-5 (ATCC<sup>&#x000ae;</sup> CCL-171&#x02122;) in EMEM with 10% FBS. Human colorectal carcinoma cell line T84 (ATCC<sup>&#x000ae;</sup> CCL-248&#x02122;) was cultured in DMEM/F12 medium with 10% FBS. Human breast cancer MCF7 (HTB-22&#x02122;) and human colorectal carcinoma cell line HCT116 (CCL-247&#x02122;) were maintained in DMEM-high glucose (Euroclone, Milan, Italy) supplemented with 10% FBS and 1% penicillin/streptomycin. Human gastric adenocarcinoma AGS cells and human prostate adenocarcinoma PC3 cells were purchased from the European Collection of Authenticated Cell Cultures (ECACC, Porton Down, Salisbury, UK) and maintained in HAM&#x02019;s F12 medium supplemented with 10% FBS and 1% of penicillin/streptomycin. Cell media and general reagents were from Euroclone S.p.A. (Pero, Milan, Italy). The positive control (-)-1 was prepared as previously described [<xref rid="B30-pharmaceuticals-18-00179" ref-type="bibr">30</xref>]. Radioactive (+)-Pentazocine (Italian Minister of Health permit to produce and use SP/072 5 April 2019) and AC927 were prepared according to published methods [<xref rid="B51-pharmaceuticals-18-00179" ref-type="bibr">51</xref>,<xref rid="B52-pharmaceuticals-18-00179" ref-type="bibr">52</xref>].</p></sec><sec id="sec4dot3-pharmaceuticals-18-00179"><title>4.3. Cell Proliferation</title><p>Cells were seeded in 96-well plates at a cell-specific density, following quantification of cell numbers on counting chambers after trypsinization and staining with trypan blue. After seeding (72 h), at a cell confluence of ~50%, the medium was removed, and treatments were started with fresh media. Treatments, carried out in quadruplicate, lasted for 48 h. Then, the cells were fixed with 4% paraformaldehyde in PBS for 20 min and, after washing, stained with either 1% crystal violet in water or an acridine orange solution (50 &#x000b5;g/mL) for an additional 20 min. At the end of the incubations, cells were washed (3 times) with 100 &#x003bc;L/well of bidistilled water. Finally, for crystal violet assays, 100 &#x003bc;L of 10% acetic acid was added to each well, and the absorbance (&#x003bb; = 590 nm) was measured with a Synergy HTX Bioteck spectrophotometer (BioSPX, Beersel, Belgium). For acridine orange assays, cell staining was evaluated by measuring the fluorescence (excitation 485/20 nm, emission 528/20 nm) with the Synergy HTX Bioteck reader.</p></sec><sec id="sec4dot4-pharmaceuticals-18-00179"><title>4.4. Radioligand Binding Assay</title><p>The <italic toggle="yes">&#x003c3;</italic><sub>1</sub>R and <italic toggle="yes">&#x003c3;</italic><sub>2</sub>R binding studies were performed as previously described [<xref rid="B30-pharmaceuticals-18-00179" ref-type="bibr">30</xref>,<xref rid="B53-pharmaceuticals-18-00179" ref-type="bibr">53</xref>,<xref rid="B54-pharmaceuticals-18-00179" ref-type="bibr">54</xref>], using guinea pig brain membranes and appropriate radioligands, including [<sup>3</sup>H]-(+)-pentazocine (45 Ci/mmol) for <italic toggle="yes">&#x003c3;</italic><sub>1</sub>R, and [<sup>3</sup>H]-1,3-di-o-tolylguanidine ([<sup>3</sup>H]-DTG; 31 Ci/mmol) for <italic toggle="yes">&#x003c3;</italic><sub>2</sub>R. Nonspecific binding was also assessed with unlabeled haloperidol or DTG. Radioactivity was determined with a Beckman LS6500 scintillation counter. Inhibition constants (Ki values) were calculated with the EBDA/LIGAND program (Elsevier/Biosoft).</p></sec><sec id="sec4dot5-pharmaceuticals-18-00179"><title>4.5. HDAC Activity Assay</title><p>HDAC activity was determined in the indicated cell lysates (50 &#x000b5;g proteins; 37 &#x000b0;C) using the non-selective HDAC Activity Colorimetric Assay kit (BioVision, Cambridge, UK), following the procedures described in previous studies [<xref rid="B23-pharmaceuticals-18-00179" ref-type="bibr">23</xref>]. Samples were read at 405 nm with a microplate reader (Multiskan GO (Thermo Fisher Scientific, Waltham, MA, USA)), and the HDAC activity was expressed as the relative optical density (O.D.) values. The IC<sub>50</sub> value of compound <bold>5c</bold> (0&#x02013;20 &#x000b5;M) in HCT116 cells was calculated using the GraphPad Prism<sup>&#x000ae;</sup> software (version 10.4.1).</p></sec><sec id="sec4dot6-pharmaceuticals-18-00179"><title>4.6. Tube Formation Assay</title><p>The tube formation assay using mouse endothelial C166 cells was analyzed employing Matrigel (BD, Bedford, MA, USA), as previously described [<xref rid="B30-pharmaceuticals-18-00179" ref-type="bibr">30</xref>]. Briefly, 96-well plates coated with Matrigel (50 &#x003bc;L/well) were filled with 100 &#x003bc;L medium/well and maintained overnight. Endothelial cells were seeded at 2.5 &#x000d7; 10<sup>4</sup> cells/well and incubated (for 3 h) with VEGF-A (80 ng/mL), in the presence of the indicated treatments. Then, capillary-like structures were imaged (&#x000d7;4 magnification) with a CCD camera connected with an inverted EVOS microscope. Finally, ImageJ software (NIH, Bethesda, MD, USA) was employed to quantify tube formations.</p></sec><sec id="sec4dot7-pharmaceuticals-18-00179"><title>4.7. Cell Spreading</title><p>Adherent 92-1 and MCF-7 cells were harvested using 0.05% Trypsin-EDTA and plated in 6-well plates. After 1 h incubations with the indicated treatments, the number of cells that formed, or not, distinct protrusions (lamellipodia, filopodia) were scored with an inverted microscope (20&#x000d7;, EVOS cell imaging system, Thermo Fisher, Waltham, MA, USA). Results were reported as either the fraction of total cell number per microscopic field (&#x02265;400 cells evaluated for each condition) or the relative percentages of inhibition of cell spreading with respect to the vehicle controls.</p></sec><sec id="sec4dot8-pharmaceuticals-18-00179"><title>4.8. Statistical Analysis</title><p>Unless otherwise specified, data were expressed as means &#x000b1; SEM of &#x02265;3 independent experiments, each conducted at least in duplicate. Student&#x02019;s <italic toggle="yes">t</italic>-test or one-way ANOVA multiple comparisons test were employed for all statistical analyses. Differences between groups were considered significant at <italic toggle="yes">p</italic> values &#x0003c; 0.05.</p></sec></sec><sec sec-type="conclusions" id="sec5-pharmaceuticals-18-00179"><title>5. Conclusions</title><p>A novel dual-target HDAC/&#x003c3;R hybrid was synthesized and investigated herein, exhibiting a single pharmacophore which simultaneously regulated HDAC and &#x003c3;<sub>1</sub>R signaling in cells. The dual-ligand preferentially suppressed melanoma cell proliferation and membrane protrusions by inhibiting HDAC-mediated epigenetic regulations and &#x003c3;<sub>1</sub>R activation, respectively. Occurrence of these effects in the same malignant cells, afforded by the dual-target strategy, is anticipated to provide synergistic opportunities for melanoma-specific eradication therapies. The novel bifunctional agent also restricted the formation of capillary-like structures in endothelial cells, an effect mediated by the selective regulation of &#x003c3;<sub>1</sub>R, and not HDAC. Future studies should explore the mechanisms of action for the dual-ligand, focusing on molecular events downstream to target engagements that underlie individual biological outcomes in tumors.</p><p>The ability to concurrently disrupt many malignant processes, including tumor growth, invasion and angiogenesis, clearly represents an advantageous trait for the dual-function HDAC/&#x003c3;<sub>1</sub>R ligand. In this way, it might provide the elusive curative, safe remedy that would shrink tumor volumes at primary sites, prevent cancer dissemination to distant organs and defeat the occurrence of tumor resistance. Translation of this therapeutic paradigm into clinical applications would contribute to the advancement of precision medicine in oncology.</p></sec></body><back><ack><title>Acknowledgments</title><p>Authors thank the Institute of Biomolecular Chemistry of the Italian National Research Center (CNR) for general technical support.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceuticals-18-00179"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/ph18020179/s1">https://www.mdpi.com/article/10.3390/ph18020179/s1</uri>; Figure S1: Inhibition of HDAC activity in HCT116, MCF7, PC3 and AGS cells by <bold>5c</bold>; Figure S2: Regulation of total tube length, nodes, and mesh area in angiogenesis assays; Figures S3 and S4: NMR spectra of synthesized compounds; Figures S5 and S6: HRMS spectra of synthesized compounds; Table S1: Cell spreading counting.</p><supplementary-material id="pharmaceuticals-18-00179-s001" position="float" content-type="local-data"><media xlink:href="pharmaceuticals-18-00179-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, G.M.P. and A.M.; methodology, C.G.L., G.M.P., A.M., E.A. and C.B.; formal analysis, C.G.L. and G.M.P.; investigation, C.G.L., C.B., J.F., A.C., V.d.G. and E.A.; data curation, C.G.L., G.M.P., A.M. and C.B.; writing&#x02014;original draft preparation, C.G.L., G.M.P. and C.B.; writing&#x02014;review and editing, G.M.P. and A.M.; supervision, G.M.P. and A.M.; funding acquisition, G.M.P. and A.M. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All data supporting the findings of the study are available from the corresponding authors, G.M.P. and A.M., upon reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>C.G.L. is an employee at Vera Salus Ricerca S.r.l. G.M.P. is a shareholder and the Chief Science Officer at Vera Salus Ricerca S.r.l. All other authors declare no conflicts of interest. The company had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</p></notes><glossary><title>Abbreviations</title><p>CM, cutaneous melanoma; UM, uveal melanoma; HDAC, histone deacetylase; &#x003c3;R, sigma receptor; VEGF, vascular endothelial growth factor; HP, haloperidol; PTZ, pentazocine; ZBG, zinc binding group; CAP, capping region; IC<sub>50</sub>, 50% inhibitory concentration; FBS, fetal bovine serum; MPLC, medium pressure liquid chromatography; NMR, nuclear magnetic resonance; HRMS, high resolution mass spectrometry; RT, room temperature.</p></glossary><ref-list><title>References</title><ref id="B1-pharmaceuticals-18-00179"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bolick</surname><given-names>N.L.</given-names></name>
<name><surname>Geller</surname><given-names>A.C.</given-names></name>
</person-group><article-title>Epidemiology of Melanoma</article-title><source>Hematol. Oncol. Clin. N. Am.</source><year>2021</year><volume>35</volume><fpage>57</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/j.hoc.2020.08.011</pub-id><pub-id pub-id-type="pmid">33759773</pub-id>
</element-citation></ref><ref id="B2-pharmaceuticals-18-00179"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Leonardi</surname><given-names>G.C.</given-names></name>
<name><surname>Falzone</surname><given-names>L.</given-names></name>
<name><surname>Salemi</surname><given-names>R.</given-names></name>
<name><surname>Zangh&#x000ec;</surname><given-names>A.</given-names></name>
<name><surname>Spandidos</surname><given-names>D.A.</given-names></name>
<name><surname>Mccubrey</surname><given-names>J.A.</given-names></name>
<name><surname>Candido</surname><given-names>S.</given-names></name>
<name><surname>Libra</surname><given-names>M.</given-names></name>
</person-group><article-title>Cutaneous melanoma: From pathogenesis to therapy (Review)</article-title><source>Int. J. Oncol.</source><year>2018</year><volume>52</volume><fpage>1071</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.3892/ijo.2018.4287</pub-id><pub-id pub-id-type="pmid">29532857</pub-id>
</element-citation></ref><ref id="B3-pharmaceuticals-18-00179"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gilchrest</surname><given-names>B.A.</given-names></name>
<name><surname>Eller</surname><given-names>M.S.</given-names></name>
<name><surname>Geller</surname><given-names>A.C.</given-names></name>
<name><surname>Yaar</surname><given-names>M.</given-names></name>
</person-group><article-title>The pathogenesis of melanoma induced by ultraviolet radiation</article-title><source>N. Engl. J. Med.</source><year>1999</year><volume>340</volume><fpage>1341</fpage><lpage>1348</lpage><pub-id pub-id-type="doi">10.1056/NEJM199904293401707</pub-id><pub-id pub-id-type="pmid">10219070</pub-id>
</element-citation></ref><ref id="B4-pharmaceuticals-18-00179"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ahmed</surname><given-names>B.</given-names></name>
<name><surname>Qadir</surname><given-names>M.I.</given-names></name>
<name><surname>Ghafoor</surname><given-names>S.</given-names></name>
</person-group><article-title>Malignant Melanoma: Skin Cancer-Diagnosis, Prevention, and Treatment</article-title><source>Crit. Rev. Eukaryot. Gene Exp.</source><year>2020</year><volume>30</volume><fpage>291</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1615/CritRevEukaryotGeneExpr.2020028454</pub-id><pub-id pub-id-type="pmid">32894659</pub-id>
</element-citation></ref><ref id="B5-pharmaceuticals-18-00179"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clark</surname><given-names>W.H.J.</given-names></name>
<name><surname>From</surname><given-names>L.</given-names></name>
<name><surname>Bernardino</surname><given-names>E.A.</given-names></name>
<name><surname>Mihm</surname><given-names>M.C.</given-names></name>
</person-group><article-title>The histogenesis and biologic behavior of primary human malignant melanomas of the skin</article-title><source>Cancer Res.</source><year>1969</year><volume>29</volume><fpage>705</fpage><lpage>727</lpage><pub-id pub-id-type="pmid">5773814</pub-id>
</element-citation></ref><ref id="B6-pharmaceuticals-18-00179"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Garbe</surname><given-names>C.</given-names></name>
<name><surname>Amaral</surname><given-names>T.</given-names></name>
<name><surname>Peris</surname><given-names>K.</given-names></name>
<name><surname>Hauschild</surname><given-names>A.</given-names></name>
<name><surname>Arenberger</surname><given-names>P.</given-names></name>
<name><surname>Basset-Seguin</surname><given-names>N.</given-names></name>
<name><surname>Bastholt</surname><given-names>L.</given-names></name>
<name><surname>Bataille</surname><given-names>V.</given-names></name>
<name><surname>del Marmol</surname><given-names>V.</given-names></name>
<name><surname>Dr&#x000e9;no</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022</article-title><source>Eur. J. Cancer</source><year>2022</year><volume>170</volume><fpage>236</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2022.03.008</pub-id><pub-id pub-id-type="pmid">35570085</pub-id>
</element-citation></ref><ref id="B7-pharmaceuticals-18-00179"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaliki</surname><given-names>S.</given-names></name>
<name><surname>Shields</surname><given-names>C.L.</given-names></name>
</person-group><article-title>Uveal melanoma: Relatively rare but deadly cancer</article-title><source>Eye</source><year>2017</year><volume>31</volume><fpage>241</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1038/eye.2016.275</pub-id><pub-id pub-id-type="pmid">27911450</pub-id>
</element-citation></ref><ref id="B8-pharmaceuticals-18-00179"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Andreoli</surname><given-names>M.T.</given-names></name>
<name><surname>Mieler</surname><given-names>W.F.</given-names></name>
<name><surname>Leiderman</surname><given-names>Y.I.</given-names></name>
</person-group><article-title>Epidemiological trends in uveal melanoma</article-title><source>Br. J. Ophthalmol.</source><year>2015</year><volume>99</volume><fpage>1550</fpage><lpage>1553</lpage><pub-id pub-id-type="doi">10.1136/bjophthalmol-2015-306810</pub-id><pub-id pub-id-type="pmid">25904122</pub-id>
</element-citation></ref><ref id="B9-pharmaceuticals-18-00179"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Palamaris</surname><given-names>K.</given-names></name>
<name><surname>Moutafi</surname><given-names>M.</given-names></name>
<name><surname>Gakiopoulou</surname><given-names>H.</given-names></name>
<name><surname>Theocharis</surname><given-names>S.</given-names></name>
</person-group><article-title>Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>3660</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23073660</pub-id><pub-id pub-id-type="pmid">35409020</pub-id>
</element-citation></ref><ref id="B10-pharmaceuticals-18-00179"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>S.Y.</given-names></name>
<name><surname>Kim</surname><given-names>J.S.</given-names></name>
</person-group><article-title>A Short Guide to Histone Deacetylases Including Recent Progress on Class II Enzymes</article-title><source>Exp. Mol. Med.</source><year>2020</year><volume>52</volume><fpage>204</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1038/s12276-020-0382-4</pub-id><pub-id pub-id-type="pmid">32071378</pub-id>
</element-citation></ref><ref id="B11-pharmaceuticals-18-00179"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilmott</surname><given-names>J.S.</given-names></name>
<name><surname>Colebatch</surname><given-names>A.J.</given-names></name>
<name><surname>Kakavand</surname><given-names>H.</given-names></name>
<name><surname>Shang</surname><given-names>P.</given-names></name>
<name><surname>Carlino</surname><given-names>M.S.</given-names></name>
<name><surname>Thompson</surname><given-names>J.F.</given-names></name>
<name><surname>Long</surname><given-names>G.V.</given-names></name>
<name><surname>Scolyer</surname><given-names>R.A.</given-names></name>
<name><surname>Hersey</surname><given-names>P.</given-names></name>
</person-group><article-title>Expression of the Class 1 Histone Deacetylases HDAC8 and 3 Are Associated with Improved Survival of Patients with Metastatic Melanoma</article-title><source>Mod. Pathol.</source><year>2015</year><volume>28</volume><fpage>884</fpage><lpage>894</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2015.34</pub-id><pub-id pub-id-type="pmid">25836739</pub-id>
</element-citation></ref><ref id="B12-pharmaceuticals-18-00179"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goutas</surname><given-names>D.</given-names></name>
<name><surname>Theocharis</surname><given-names>S.</given-names></name>
<name><surname>Tsourouflis</surname><given-names>G.</given-names></name>
</person-group><article-title>Unraveling the Epigenetic Role and Clinical Impact of Histone Deacetylases in Neoplasia</article-title><source>Diagnostics</source><year>2021</year><volume>11</volume><elocation-id>1346</elocation-id><pub-id pub-id-type="doi">10.3390/diagnostics11081346</pub-id><pub-id pub-id-type="pmid">34441281</pub-id>
</element-citation></ref><ref id="B13-pharmaceuticals-18-00179"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gatti</surname><given-names>L.</given-names></name>
<name><surname>Sevko</surname><given-names>A.</given-names></name>
<name><surname>de Cesare</surname><given-names>M.</given-names></name>
<name><surname>Arrighetti</surname><given-names>N.</given-names></name>
<name><surname>Manenti</surname><given-names>G.</given-names></name>
<name><surname>Ciusani</surname><given-names>E.</given-names></name>
<name><surname>Verderio</surname><given-names>P.</given-names></name>
<name><surname>Ciniselli</surname><given-names>C.M.</given-names></name>
<name><surname>Cominetti</surname><given-names>D.</given-names></name>
<name><surname>Carenini</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Histone Deacetylase Inhibitor-Temozolomide Co-Treatment Inhibits Melanoma Growth through Suppression of Chemokine (C-C Motif) Ligand 2-Driven Signals</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><fpage>4516</fpage><lpage>4528</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2065</pub-id><pub-id pub-id-type="pmid">24980831</pub-id>
</element-citation></ref><ref id="B14-pharmaceuticals-18-00179"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Souri</surname><given-names>Z.</given-names></name>
<name><surname>Jochemsen</surname><given-names>A.G.</given-names></name>
<name><surname>Versluis</surname><given-names>M.</given-names></name>
<name><surname>Wierenga</surname><given-names>A.P.A.</given-names></name>
<name><surname>Nemati</surname><given-names>F.</given-names></name>
<name><surname>van der Velden</surname><given-names>P.A.</given-names></name>
<name><surname>Kroes</surname><given-names>W.G.M.</given-names></name>
<name><surname>Verdijk</surname><given-names>R.M.</given-names></name>
<name><surname>Luyten</surname><given-names>G.P.M.</given-names></name>
<name><surname>Jager</surname><given-names>M.J.</given-names></name>
</person-group><article-title>HDAC Inhibition Increases HLA Class I Expression in Uveal Melanoma</article-title><source>Cancers</source><year>2020</year><volume>12</volume><elocation-id>3690</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12123690</pub-id><pub-id pub-id-type="pmid">33316946</pub-id>
</element-citation></ref><ref id="B15-pharmaceuticals-18-00179"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ny</surname><given-names>L.</given-names></name>
<name><surname>Jespersen</surname><given-names>H.</given-names></name>
<name><surname>Karlsson</surname><given-names>J.</given-names></name>
<name><surname>Als&#x000e9;n</surname><given-names>S.</given-names></name>
<name><surname>Filges</surname><given-names>S.</given-names></name>
<name><surname>All-Eriksson</surname><given-names>C.</given-names></name>
<name><surname>Andersson</surname><given-names>B.</given-names></name>
<name><surname>Carneiro</surname><given-names>A.</given-names></name>
<name><surname>Helgadottir</surname><given-names>H.</given-names></name>
<name><surname>Levin</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>The PEMDAC Phase 2 Study of Pembrolizumab and Entinostat in Patients with Metastatic Uveal Melanoma</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>5155</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-25332-w</pub-id><pub-id pub-id-type="pmid">34453044</pub-id>
</element-citation></ref><ref id="B16-pharmaceuticals-18-00179"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ibrahim</surname><given-names>N.</given-names></name>
<name><surname>Buchbinder</surname><given-names>E.I.</given-names></name>
<name><surname>Granter</surname><given-names>S.R.</given-names></name>
<name><surname>Rodig</surname><given-names>S.J.</given-names></name>
<name><surname>Giobbie-Hurder</surname><given-names>A.</given-names></name>
<name><surname>Becerra</surname><given-names>C.</given-names></name>
<name><surname>Tsiaras</surname><given-names>A.</given-names></name>
<name><surname>Gjini</surname><given-names>E.</given-names></name>
<name><surname>Fisher</surname><given-names>D.E.</given-names></name>
<name><surname>Hodi</surname><given-names>F.S.</given-names></name>
</person-group><article-title>A Phase I Trial of Panobinostat (LBH589) in Patients with Metastatic Melanoma</article-title><source>Cancer Med.</source><year>2016</year><volume>5</volume><fpage>3041</fpage><lpage>3050</lpage><pub-id pub-id-type="doi">10.1002/cam4.862</pub-id><pub-id pub-id-type="pmid">27748045</pub-id>
</element-citation></ref><ref id="B17-pharmaceuticals-18-00179"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gallinari</surname><given-names>P.</given-names></name>
<name><surname>Marco</surname><given-names>S.</given-names></name>
<name><surname>Jones</surname><given-names>P.</given-names></name>
<name><surname>Pallaoro</surname><given-names>M.</given-names></name>
<name><surname>Steink&#x000fc;hler</surname><given-names>C.</given-names></name>
</person-group><article-title>HDACs, histone deacetylation and gene transcription: From molecular biology to cancer therapeutics</article-title><source>Cell Res.</source><year>2007</year><volume>17</volume><fpage>195</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1038/sj.cr.7310149</pub-id><pub-id pub-id-type="pmid">17325692</pub-id>
</element-citation></ref><ref id="B18-pharmaceuticals-18-00179"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Souri</surname><given-names>Z.</given-names></name>
<name><surname>Jochemsen</surname><given-names>A.G.</given-names></name>
<name><surname>Wierenga</surname><given-names>A.P.A.</given-names></name>
<name><surname>Kroes</surname><given-names>W.G.M.</given-names></name>
<name><surname>Verdijk</surname><given-names>R.M.</given-names></name>
<name><surname>van der Velden</surname><given-names>P.A.</given-names></name>
<name><surname>Luyten</surname><given-names>G.P.M.</given-names></name>
<name><surname>Jager</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Expression of Hdacs 1, 3 and 8 Is Upregulated in the Presence of Infiltrating Lymphocytes in Uveal Melanoma</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>4146</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13164146</pub-id><pub-id pub-id-type="pmid">34439300</pub-id>
</element-citation></ref><ref id="B19-pharmaceuticals-18-00179"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eckschlager</surname><given-names>T.</given-names></name>
<name><surname>Plch</surname><given-names>J.</given-names></name>
<name><surname>Stiborova</surname><given-names>M.</given-names></name>
<name><surname>Hrabeta</surname><given-names>J.</given-names></name>
</person-group><article-title>Histone Deacetylase Inhibitors as Anticancer Drugs</article-title><source>Int. J. Mol. Sci.</source><year>2017</year><volume>18</volume><elocation-id>1414</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18071414</pub-id><pub-id pub-id-type="pmid">28671573</pub-id>
</element-citation></ref><ref id="B20-pharmaceuticals-18-00179"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Venugopal</surname><given-names>B.</given-names></name>
<name><surname>Baird</surname><given-names>R.</given-names></name>
<name><surname>Kristeleit</surname><given-names>R.S.</given-names></name>
<name><surname>Plummer</surname><given-names>R.</given-names></name>
<name><surname>Cowan</surname><given-names>R.</given-names></name>
<name><surname>Stewart</surname><given-names>A.</given-names></name>
<name><surname>Fourneau</surname><given-names>N.</given-names></name>
<name><surname>Hellemans</surname><given-names>P.</given-names></name>
<name><surname>Elsayed</surname><given-names>Y.</given-names></name>
<name><surname>McClue</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>A phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors</article-title><source>Clin. Cancer Res.</source><year>2013</year><volume>19</volume><fpage>4262</fpage><lpage>4272</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-0312</pub-id><pub-id pub-id-type="pmid">23741066</pub-id>
</element-citation></ref><ref id="B21-pharmaceuticals-18-00179"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cho</surname><given-names>W.C.</given-names></name>
<name><surname>Jour</surname><given-names>G.</given-names></name>
<name><surname>Aung</surname><given-names>P.P.</given-names></name>
</person-group><article-title>Role of angiogenesis in melanoma progression: Update on key angiogenic mechanisms and other associated components</article-title><source>Semin. Cancer Biol.</source><year>2019</year><volume>59</volume><fpage>175</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2019.06.015</pub-id><pub-id pub-id-type="pmid">31255774</pub-id>
</element-citation></ref><ref id="B22-pharmaceuticals-18-00179"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tarhini</surname><given-names>A.A.</given-names></name>
<name><surname>Frankel</surname><given-names>P.</given-names></name>
<name><surname>Margolin</surname><given-names>K.A.</given-names></name>
<name><surname>Christensen</surname><given-names>S.</given-names></name>
<name><surname>Ruel</surname><given-names>C.</given-names></name>
<name><surname>Shipe-Spotloe</surname><given-names>J.</given-names></name>
<name><surname>Gandara</surname><given-names>D.R.</given-names></name>
<name><surname>Chen</surname><given-names>A.</given-names></name>
<name><surname>Kirkwood</surname><given-names>J.M.</given-names></name>
</person-group><article-title>Aflibercept (VEGF Trap) in inoperable stage III or stage IV melanoma of cutaneous or uveal origin</article-title><source>Clin. Cancer Res.</source><year>2011</year><volume>17</volume><fpage>6574</fpage><lpage>6581</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-1463</pub-id><pub-id pub-id-type="pmid">21880788</pub-id>
</element-citation></ref><ref id="B23-pharmaceuticals-18-00179"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barbaraci</surname><given-names>C.</given-names></name>
<name><surname>di Giacomo</surname><given-names>V.</given-names></name>
<name><surname>Maruca</surname><given-names>A.</given-names></name>
<name><surname>Patamia</surname><given-names>V.</given-names></name>
<name><surname>Rocca</surname><given-names>R.</given-names></name>
<name><surname>Dichiara</surname><given-names>M.</given-names></name>
<name><surname>Di Rienzo</surname><given-names>A.</given-names></name>
<name><surname>Cacciatore</surname><given-names>I.</given-names></name>
<name><surname>Cataldi</surname><given-names>A.</given-names></name>
<name><surname>Balaha</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Discovery of first novel sigma/HDACi dual-ligands with a potent in vitro antiproliferative activity</article-title><source>Bioorg. Chem.</source><year>2023</year><volume>140</volume><elocation-id>106794</elocation-id><pub-id pub-id-type="doi">10.1016/j.bioorg.2023.106794</pub-id><pub-id pub-id-type="pmid">37659146</pub-id>
</element-citation></ref><ref id="B24-pharmaceuticals-18-00179"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rousseaux</surname><given-names>C.G.</given-names></name>
<name><surname>Greene</surname><given-names>S.F.</given-names></name>
</person-group><article-title>Sigma receptors [&#x003c3;Rs]: Biology in normal and diseased states</article-title><source>J. Recept. Signal Transduct. Res.</source><year>2016</year><volume>36</volume><fpage>327</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.3109/10799893.2015.1015737</pub-id><pub-id pub-id-type="pmid">26056947</pub-id>
</element-citation></ref><ref id="B25-pharmaceuticals-18-00179"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hanner</surname><given-names>M.</given-names></name>
<name><surname>Moebius</surname><given-names>F.F.</given-names></name>
<name><surname>Flandorfer</surname><given-names>A.</given-names></name>
<name><surname>Knaus</surname><given-names>H.G.</given-names></name>
<name><surname>Striessnig</surname><given-names>J.</given-names></name>
<name><surname>Kempner</surname><given-names>E.</given-names></name>
<name><surname>Glossmann</surname><given-names>H.</given-names></name>
</person-group><article-title>Purification, molecular cloning, and expression of the mammalian sigma1-binding site</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1996</year><volume>93</volume><fpage>8072</fpage><lpage>8077</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.15.8072</pub-id><pub-id pub-id-type="pmid">8755605</pub-id>
</element-citation></ref><ref id="B26-pharmaceuticals-18-00179"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alon</surname><given-names>A.</given-names></name>
<name><surname>Schmidt</surname><given-names>H.R.</given-names></name>
<name><surname>Wood</surname><given-names>M.D.</given-names></name>
<name><surname>Sahn</surname><given-names>J.J.</given-names></name>
<name><surname>Martin</surname><given-names>S.F.</given-names></name>
<name><surname>Kruse</surname><given-names>A.C.</given-names></name>
</person-group><article-title>Identification of the gene that codes for the &#x003c3; 2 receptor</article-title><source>Proc. Natl. Acad. Sci. USA.</source><year>2017</year><volume>114</volume><fpage>7160</fpage><lpage>7165</lpage><pub-id pub-id-type="doi">10.1073/pnas.1705154114</pub-id><pub-id pub-id-type="pmid">28559337</pub-id>
</element-citation></ref><ref id="B27-pharmaceuticals-18-00179"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Borde</surname><given-names>P.</given-names></name>
<name><surname>Cosgrove</surname><given-names>N.</given-names></name>
<name><surname>Charmsaz</surname><given-names>S.</given-names></name>
<name><surname>Safrany</surname><given-names>S.T.</given-names></name>
<name><surname>Young</surname><given-names>L.</given-names></name>
</person-group><article-title>An investigation of Sigma-1 receptor expression and ligand-induced endoplasmic reticulum stress in breast cancer</article-title><source>Cancer Gene Ther.</source><year>2023</year><volume>30</volume><fpage>368</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1038/s41417-022-00552-4</pub-id><pub-id pub-id-type="pmid">36352093</pub-id>
</element-citation></ref><ref id="B28-pharmaceuticals-18-00179"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>K.</given-names></name>
<name><surname>Zeng</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Sun</surname><given-names>M.</given-names></name>
<name><surname>Yin</surname><given-names>D.</given-names></name>
<name><surname>Sun</surname><given-names>T.</given-names></name>
</person-group><article-title>Sigma-2 Receptor&#x02014;A Potential Target for Cancer/Alzheimer&#x02019;s Disease Treatment via Its Regulation of Cholesterol Homeostasis</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>5439</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25225439</pub-id><pub-id pub-id-type="pmid">33233619</pub-id>
</element-citation></ref><ref id="B29-pharmaceuticals-18-00179"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Georgiadis</surname><given-names>M.-O.</given-names></name>
<name><surname>Karoutzou</surname><given-names>O.</given-names></name>
<name><surname>Foscolos</surname><given-names>A.-S.</given-names></name>
<name><surname>Papanastasiou</surname><given-names>I.</given-names></name>
</person-group><article-title>Sigma Receptor (&#x003c3;R) Ligands with Antiproliferative and Anticancer Activity</article-title><source>Molecules</source><year>2017</year><volume>22</volume><elocation-id>1408</elocation-id><pub-id pub-id-type="doi">10.3390/molecules22091408</pub-id><pub-id pub-id-type="pmid">28841173</pub-id>
</element-citation></ref><ref id="B30-pharmaceuticals-18-00179"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barbaraci</surname><given-names>C.</given-names></name>
<name><surname>Giurdanella</surname><given-names>G.</given-names></name>
<name><surname>Leotta</surname><given-names>C.G.</given-names></name>
<name><surname>Longo</surname><given-names>A.</given-names></name>
<name><surname>Amata</surname><given-names>E.</given-names></name>
<name><surname>Dichiara</surname><given-names>M.</given-names></name>
<name><surname>Pasquinucci</surname><given-names>L.</given-names></name>
<name><surname>Turnaturi</surname><given-names>R.</given-names></name>
<name><surname>Prezzavento</surname><given-names>O.</given-names></name>
<name><surname>Cacciatore</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Haloperidol Metabolite II Valproate Ester (S)-(-)-MRJF22: Preliminary Studies as a Potential Multifunctional Agent Against Uveal Melanoma</article-title><source>J. Med. Chem.</source><year>2021</year><volume>64</volume><fpage>13622</fpage><lpage>13632</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c00995</pub-id><pub-id pub-id-type="pmid">34477381</pub-id>
</element-citation></ref><ref id="B31-pharmaceuticals-18-00179"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Longhitano</surname><given-names>L.</given-names></name>
<name><surname>Castracani</surname><given-names>C.C.</given-names></name>
<name><surname>Tibullo</surname><given-names>D.</given-names></name>
<name><surname>Avola</surname><given-names>R.</given-names></name>
<name><surname>Viola</surname><given-names>M.</given-names></name>
<name><surname>Russo</surname><given-names>G.</given-names></name>
<name><surname>Prezzavento</surname><given-names>O.</given-names></name>
<name><surname>Marrazzo</surname><given-names>A.</given-names></name>
<name><surname>Amata</surname><given-names>E.</given-names></name>
<name><surname>Reibaldi</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Sigma-1 and Sigma-2 receptor ligands induce apoptosis and autophagy but have opposite effect on cell proliferation in uveal melanoma</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>91099</fpage><lpage>91111</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.19556</pub-id><pub-id pub-id-type="pmid">29207628</pub-id>
</element-citation></ref><ref id="B32-pharmaceuticals-18-00179"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miller</surname><given-names>T.A.</given-names></name>
<name><surname>Witter</surname><given-names>D.J.</given-names></name>
<name><surname>Belvedere</surname><given-names>S.</given-names></name>
</person-group><article-title>Histone deacetylase inhibitors</article-title><source>J. Med. Chem.</source><year>2003</year><volume>46</volume><fpage>5097</fpage><lpage>5116</lpage><pub-id pub-id-type="doi">10.1021/jm0303094</pub-id><pub-id pub-id-type="pmid">14613312</pub-id>
</element-citation></ref><ref id="B33-pharmaceuticals-18-00179"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mai</surname><given-names>A.</given-names></name>
<name><surname>Massa</surname><given-names>S.</given-names></name>
<name><surname>Rotili</surname><given-names>D.</given-names></name>
<name><surname>Pezzi</surname><given-names>R.</given-names></name>
<name><surname>Bottoni</surname><given-names>P.</given-names></name>
<name><surname>Scatena</surname><given-names>R.</given-names></name>
<name><surname>Meraner</surname><given-names>J.</given-names></name>
<name><surname>Brosch</surname><given-names>G.</given-names></name>
</person-group><article-title>Exploring the connection unit in the HDAC inhibitor pharmacophore model: Novel uracil-based hydroxamates</article-title><source>Bioorg. Med. Chem. Lett.</source><year>2005</year><volume>15</volume><fpage>4656</fpage><lpage>4661</lpage><pub-id pub-id-type="doi">10.1016/j.bmcl.2005.07.081</pub-id><pub-id pub-id-type="pmid">16165353</pub-id>
</element-citation></ref><ref id="B34-pharmaceuticals-18-00179"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Glennon</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Pharmacophore identification for sigma-1 (sigma1) receptor binding: Application of the &#x0201c;deconstruction-reconstruction-elaboration&#x0201d; approach. Mini Rev</article-title><source>Med. Chem.</source><year>2005</year><volume>5</volume><fpage>927</fpage><lpage>940</lpage></element-citation></ref><ref id="B35-pharmaceuticals-18-00179"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gasparre</surname><given-names>G.</given-names></name>
<name><surname>Abate</surname><given-names>C.</given-names></name>
<name><surname>Carlucci</surname><given-names>R.</given-names></name>
<name><surname>Berardi</surname><given-names>F.</given-names></name>
<name><surname>Cassano</surname><given-names>G.</given-names></name>
</person-group><article-title>The &#x003c3;<sub>1</sub> receptor agonist (+)-pentazocine increases store-operated Ca<sup>2</sup>+ entry in MCF7&#x003c3;1 and SK-N-SH cell lines</article-title><source>Pharmacol. Rep.</source><year>2017</year><volume>69</volume><fpage>542</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1016/j.pharep.2017.01.022</pub-id><pub-id pub-id-type="pmid">28364693</pub-id>
</element-citation></ref><ref id="B36-pharmaceuticals-18-00179"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vigushin</surname><given-names>D.M.</given-names></name>
<name><surname>Ali</surname><given-names>S.</given-names></name>
<name><surname>Pace</surname><given-names>P.E.</given-names></name>
<name><surname>Mirsaidi</surname><given-names>N.</given-names></name>
<name><surname>Ito</surname><given-names>K.</given-names></name>
<name><surname>Adcock</surname><given-names>I.</given-names></name>
<name><surname>Coombes</surname><given-names>R.C.</given-names></name>
</person-group><article-title>Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo</article-title><source>Clin. Cancer Res.</source><year>2001</year><volume>7</volume><fpage>971</fpage><lpage>976</lpage><pub-id pub-id-type="pmid">11309348</pub-id>
</element-citation></ref><ref id="B37-pharmaceuticals-18-00179"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Levinzon</surname><given-names>L.</given-names></name>
<name><surname>Madigan</surname><given-names>M.</given-names></name>
<name><surname>Nguyen</surname><given-names>V.</given-names></name>
<name><surname>Hasic</surname><given-names>E.</given-names></name>
<name><surname>Conway</surname><given-names>M.</given-names></name>
<name><surname>Cherepanoff</surname><given-names>S.</given-names></name>
</person-group><article-title>Tumour Expression of Histone Deacetylases in Uveal Melanoma</article-title><source>Ocul. Oncol. Pathol.</source><year>2019</year><volume>5</volume><fpage>153</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1159/000490038</pub-id><pub-id pub-id-type="pmid">31049320</pub-id>
</element-citation></ref><ref id="B38-pharmaceuticals-18-00179"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crawford</surname><given-names>K.W.</given-names></name>
<name><surname>Coop</surname><given-names>A.</given-names></name>
<name><surname>Bowen</surname><given-names>W.D.</given-names></name>
</person-group><article-title>Sigma(2)Receptors regulate changes in sphingolipid levels in breast tumor cells</article-title><source>Eur. J. Pharmacol.</source><year>2002</year><volume>443</volume><fpage>207</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/S0014-2999(02)01581-9</pub-id><pub-id pub-id-type="pmid">12044812</pub-id>
</element-citation></ref><ref id="B39-pharmaceuticals-18-00179"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCollum</surname><given-names>C.W.</given-names></name>
<name><surname>Conde-Vancells</surname><given-names>J.</given-names></name>
<name><surname>Hans</surname><given-names>C.</given-names></name>
<name><surname>Vazquez-Chantada</surname><given-names>M.</given-names></name>
<name><surname>Kleinstreuer</surname><given-names>N.</given-names></name>
<name><surname>Tal</surname><given-names>T.</given-names></name>
<name><surname>Knudsen</surname><given-names>T.</given-names></name>
<name><surname>Shah</surname><given-names>S.S.</given-names></name>
<name><surname>Merchant</surname><given-names>F.A.</given-names></name>
<name><surname>Finnell</surname><given-names>R.H.</given-names></name>
<etal/>
</person-group><article-title>Identification of vascular disruptor compounds by analysis in zebrafish embryos and mouse embryonic endothelial cells</article-title><source>Reprod. Toxicol.</source><year>2017</year><volume>70</volume><fpage>60</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.reprotox.2016.11.005</pub-id><pub-id pub-id-type="pmid">27838387</pub-id>
</element-citation></ref><ref id="B40-pharmaceuticals-18-00179"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ikawa</surname><given-names>T.</given-names></name>
<name><surname>Miyagawa</surname><given-names>T.</given-names></name>
<name><surname>Fukui</surname><given-names>Y.</given-names></name>
<name><surname>Toyama</surname><given-names>S.</given-names></name>
<name><surname>Omatsu</surname><given-names>J.</given-names></name>
<name><surname>Awaji</surname><given-names>K.</given-names></name>
<name><surname>Norimatsu</surname><given-names>Y.</given-names></name>
<name><surname>Watanabe</surname><given-names>Y.</given-names></name>
<name><surname>Yoshizaki</surname><given-names>A.</given-names></name>
<name><surname>Sato</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Endothelial CCR6 expression due to FLI1 deficiency contributes to vasculopathy associated with systemic sclerosis</article-title><source>Arthritis Res. Ther.</source><year>2021</year><volume>23</volume><fpage>283</fpage><pub-id pub-id-type="doi">10.1186/s13075-021-02667-9</pub-id><pub-id pub-id-type="pmid">34774095</pub-id>
</element-citation></ref><ref id="B41-pharmaceuticals-18-00179"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Flavahan</surname><given-names>W.A.</given-names></name>
<name><surname>Gaskell</surname><given-names>E.</given-names></name>
<name><surname>Bernstein</surname><given-names>B.E.</given-names></name>
</person-group><article-title>Epigenetic Plasticity and the Hallmarks of Cancer</article-title><source>Science</source><year>2017</year><volume>357</volume><fpage>eaal2380</fpage><pub-id pub-id-type="doi">10.1126/science.aal2380</pub-id><pub-id pub-id-type="pmid">28729483</pub-id>
</element-citation></ref><ref id="B42-pharmaceuticals-18-00179"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lubbe</surname><given-names>W.J.</given-names></name>
<name><surname>Zhou</surname><given-names>Z.Y.</given-names></name>
<name><surname>Fu</surname><given-names>W.</given-names></name>
<name><surname>Zuzga</surname><given-names>D.</given-names></name>
<name><surname>Schulz</surname><given-names>S.</given-names></name>
<name><surname>Fridman</surname><given-names>R.</given-names></name>
<name><surname>Muschel</surname><given-names>R.J.</given-names></name>
<name><surname>Waldman</surname><given-names>S.A.</given-names></name>
<name><surname>Pitari</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Tumor Epithelial Cell Matrix Metalloproteinase 9 Is a Target for Antimetastatic Therapy in Colorectal Cancer</article-title><source>Clin. Cancer Res.</source><year>2006</year><volume>12</volume><fpage>1876</fpage><lpage>1882</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-2686</pub-id><pub-id pub-id-type="pmid">16551873</pub-id>
</element-citation></ref><ref id="B43-pharmaceuticals-18-00179"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pihl</surname><given-names>E.</given-names></name>
<name><surname>Hughes</surname><given-names>E.S.</given-names></name>
<name><surname>McDermott</surname><given-names>F.T.</given-names></name>
<name><surname>Milne</surname><given-names>B.J.</given-names></name>
<name><surname>Price</surname><given-names>A.B.</given-names></name>
</person-group><article-title>Disease-free survival and recurrence after resection of colorectal carcinoma</article-title><source>J. Surg. Oncol.</source><year>1981</year><volume>16</volume><fpage>333</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1002/jso.2930160406</pub-id><pub-id pub-id-type="pmid">7253653</pub-id>
</element-citation></ref><ref id="B44-pharmaceuticals-18-00179"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCawley</surname><given-names>L.J.</given-names></name>
<name><surname>Matrisian</surname><given-names>L.M.</given-names></name>
</person-group><article-title>Matrix metalloproteinases: They&#x02019;re not just for matrix anymore!</article-title><source>Curr. Opin. Cell Biol.</source><year>2001</year><volume>13</volume><fpage>534</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1016/S0955-0674(00)00248-9</pub-id><pub-id pub-id-type="pmid">11544020</pub-id>
</element-citation></ref><ref id="B45-pharmaceuticals-18-00179"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Bai</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Zhu</surname><given-names>C.</given-names></name>
<name><surname>Wu</surname><given-names>Z.P.</given-names></name>
</person-group><article-title>Overexpression of sigma-1 receptor in MCF-7 cells enhances proliferation via the classic protein kinase C subtype signaling pathway</article-title><source>Oncol. Lett.</source><year>2018</year><volume>16</volume><fpage>6763</fpage><lpage>6769</lpage><pub-id pub-id-type="doi">10.3892/ol.2018.9448</pub-id><pub-id pub-id-type="pmid">30405820</pub-id>
</element-citation></ref><ref id="B46-pharmaceuticals-18-00179"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Glozak</surname><given-names>M.</given-names></name>
<name><surname>Seto</surname><given-names>E.</given-names></name>
</person-group><article-title>Histone deacetylases and cancer</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>5420</fpage><lpage>5432</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210610</pub-id><pub-id pub-id-type="pmid">17694083</pub-id>
</element-citation></ref><ref id="B47-pharmaceuticals-18-00179"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Oyer</surname><given-names>H.M.</given-names></name>
<name><surname>Sanders</surname><given-names>C.M.</given-names></name>
<name><surname>Kim</surname><given-names>F.J.</given-names></name>
</person-group><article-title>Small-Molecule Modulators of Sigma1 and Sigma2/TMEM97 in the Context of Cancer: Foundational Concepts and Emerging Themes</article-title><source>Front. Pharmacol.</source><year>2019</year><volume>10</volume><elocation-id>1141</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2019.01141</pub-id><pub-id pub-id-type="pmid">31695608</pub-id>
</element-citation></ref><ref id="B48-pharmaceuticals-18-00179"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Crott&#x000e8;s</surname><given-names>D.</given-names></name>
<name><surname>Rapetti-Mauss</surname><given-names>R.</given-names></name>
<name><surname>Alcaraz-Perez</surname><given-names>F.</given-names></name>
<name><surname>Tichet</surname><given-names>M.</given-names></name>
<name><surname>Gariano</surname><given-names>G.</given-names></name>
<name><surname>Martial</surname><given-names>S.</given-names></name>
<name><surname>Guizouarn</surname><given-names>H.</given-names></name>
<name><surname>Pellissier</surname><given-names>B.</given-names></name>
<name><surname>Loubat</surname><given-names>A.</given-names></name>
<name><surname>Popa</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>SIGMAR1 Regulates Membrane Electrical Activity in Response to Extracellular Matrix Stimulation to Drive Cancer Cell Invasiveness</article-title><source>Cancer Res.</source><year>2016</year><volume>76</volume><fpage>607</fpage><lpage>618</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-1465</pub-id><pub-id pub-id-type="pmid">26645564</pub-id>
</element-citation></ref><ref id="B49-pharmaceuticals-18-00179"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>Q.X.</given-names></name>
<name><surname>Li</surname><given-names>E.M.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.F.</given-names></name>
<name><surname>Liao</surname><given-names>L.D.</given-names></name>
<name><surname>Xu</surname><given-names>X.E.</given-names></name>
<name><surname>Wu</surname><given-names>Z.Y.</given-names></name>
<name><surname>Shen</surname><given-names>J.H.</given-names></name>
<name><surname>Xu</surname><given-names>L.Y.</given-names></name>
</person-group><article-title>Overexpression of sigma1 receptor and its positive associations with pathologic TNM classification in esophageal squamous cell carcinoma</article-title><source>J. Histochem. Cytochem.</source><year>2012</year><volume>60</volume><fpage>457</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1369/0022155412443542</pub-id><pub-id pub-id-type="pmid">22511599</pub-id>
</element-citation></ref><ref id="B50-pharmaceuticals-18-00179"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moody</surname><given-names>T.W.</given-names></name>
<name><surname>Leyton</surname><given-names>J.</given-names></name>
<name><surname>John</surname><given-names>C.</given-names></name>
</person-group><article-title>Sigma ligands inhibit the growth of small cell lung cancer cells</article-title><source>Life Sci.</source><year>2000</year><volume>66</volume><fpage>1979</fpage><lpage>1986</lpage><pub-id pub-id-type="doi">10.1016/S0024-3205(00)00523-3</pub-id><pub-id pub-id-type="pmid">10821122</pub-id>
</element-citation></ref><ref id="B51-pharmaceuticals-18-00179"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matsumoto</surname><given-names>R.R.</given-names></name>
<name><surname>Bowen</surname><given-names>W.D.</given-names></name>
<name><surname>Tom</surname><given-names>M.A.</given-names></name>
<name><surname>Vo</surname><given-names>V.N.</given-names></name>
<name><surname>Truong</surname><given-names>D.D.</given-names></name>
<name><surname>De Costa</surname><given-names>B.R.</given-names></name>
</person-group><article-title>Characterization of two novel sigma receptor ligands: Antidystonic effects in rats suggest sigma receptor antagonism</article-title><source>Eur. J. Pharmacol.</source><year>1995</year><volume>280</volume><fpage>301</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(95)00208-3</pub-id><pub-id pub-id-type="pmid">8566098</pub-id>
</element-citation></ref><ref id="B52-pharmaceuticals-18-00179"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anfuso</surname><given-names>C.D.</given-names></name>
<name><surname>Longo</surname><given-names>A.</given-names></name>
<name><surname>Distefano</surname><given-names>A.</given-names></name>
<name><surname>Amorini</surname><given-names>A.M.</given-names></name>
<name><surname>Salmeri</surname><given-names>M.</given-names></name>
<name><surname>Zanghi</surname><given-names>G.</given-names></name>
<name><surname>Giallongo</surname><given-names>C.</given-names></name>
<name><surname>Giurdanella</surname><given-names>G.</given-names></name>
<name><surname>Lupo</surname><given-names>G.</given-names></name>
</person-group><article-title>Uveal Melanoma Cells Elicit Retinal Pericyte Phenotypical and Biochemical Changes in an in Vitro Model of Coculture</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>5557</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21155557</pub-id><pub-id pub-id-type="pmid">32756477</pub-id>
</element-citation></ref><ref id="B53-pharmaceuticals-18-00179"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rossi</surname><given-names>M.</given-names></name>
<name><surname>Petralla</surname><given-names>S.</given-names></name>
<name><surname>Protti</surname><given-names>M.</given-names></name>
<name><surname>Baiula</surname><given-names>M.</given-names></name>
<name><surname>Kobrlova</surname><given-names>T.</given-names></name>
<name><surname>Soukup</surname><given-names>O.</given-names></name>
<name><surname>Spampinato</surname><given-names>S.M.</given-names></name>
<name><surname>Mercolini</surname><given-names>L.</given-names></name>
<name><surname>Monti</surname><given-names>B.</given-names></name>
<name><surname>Bolognesi</surname><given-names>M.L.</given-names></name>
</person-group><article-title>Alpha-linolenic acid-valproic acid conjugates: Toward single-molecule polypharmacology for multiple sclerosis</article-title><source>ACS Med. Chem. Lett.</source><year>2020</year><volume>11</volume><fpage>2406</fpage><lpage>2413</lpage><pub-id pub-id-type="doi">10.1021/acsmedchemlett.0c00375</pub-id><pub-id pub-id-type="pmid">33329762</pub-id>
</element-citation></ref><ref id="B54-pharmaceuticals-18-00179"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mach</surname><given-names>R.H.</given-names></name>
<name><surname>Smith</surname><given-names>C.R.</given-names></name>
<name><surname>Childers</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Ibogaine possesses a selective affinity for sigma 2 receptors</article-title><source>Life Sci.</source><year>1995</year><volume>57</volume><fpage>PL57</fpage><lpage>PL62</lpage><pub-id pub-id-type="doi">10.1016/0024-3205(95)00301-L</pub-id><pub-id pub-id-type="pmid">7603301</pub-id>
</element-citation></ref></ref-list><sec sec-type="display-objects"><title>Figures, Scheme and Tables</title><fig position="float" id="pharmaceuticals-18-00179-f001"><label>Figure 1</label><caption><p>Chemical scaffolds and molecular design for dual-function hybrid <bold>5c</bold>.</p></caption><graphic xlink:href="pharmaceuticals-18-00179-g001" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00179-sch001"><object-id pub-id-type="pii">pharmaceuticals-18-00179-sch001_Scheme 1</object-id><label>Scheme 1</label><caption><p>Synthesis of the dual-ligand compound <bold>5c</bold> (<bold>5</bold>) and its precursor <bold>3c</bold> (<bold>3</bold>). All reactions were performed at room temperature (RT). Principal reagents employed: (i) MeI, DMF, RT; (ii) AcOH, NaBH(OAc)<sub>3</sub>, THF, RT; (iii) 1. LiOH 1 M, MeOH, RT; 2. ClCO<sub>2</sub>Et, TEA, THF, RT; 3. NH<sub>2</sub>OTHP, THF, RT; (iv) HCl 1.25 M.</p></caption><graphic xlink:href="pharmaceuticals-18-00179-sch001" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00179-f002"><label>Figure 2</label><caption><p>Characterization of HDACi and the anticancer pharmacology by the dual-target hybrid <bold>5c</bold>. (<bold>a</bold>) Dose&#x02013;response curve of <bold>5c</bold> on total HDAC activity in HCT116 cells. HDAC enzymatic activity was measured as described in Materials and Methods. (<bold>b</bold>) Antiproliferative dose&#x02013;response curves of <bold>5c</bold> in UM 92-1 (3, 10, 30, 100 and 300 nM) and MRC-5 (30, 100, 300, 1000 and 3000 nM) cells. (<bold>c</bold>) Antiproliferative dose&#x02013;response curves of <bold>5c</bold> (1, 3, 10, 30 and 100 nM) in various human cancer and normal cell lines. In (<bold>b</bold>,<bold>c</bold>), treatments were performed for 48 h, and proliferation was assessed using the crystal violet assay and spectrophotometry (with absorbance at 590 nm). Data were expressed as the percentage of the vehicle control (DMSO) and organized on a log scale. (<bold>d</bold>) Heat map representation of antiproliferative IC<sub>50</sub> values calculated for <bold>5c</bold> in each of the five cancer cell lines investigated.</p></caption><graphic xlink:href="pharmaceuticals-18-00179-g002" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00179-f003"><label>Figure 3</label><caption><p>Assessment of the pharmacological antiproliferative target for <bold>5c</bold> in human melanoma cells. (<bold>a</bold>) Proliferation of UM 92-1 cells exposed to <bold>5c</bold> (30 nM) alone or in combination with selective &#x003c3;<sub>1</sub>R agonist pentazocine (PTZ, 2 &#x003bc;M) or &#x003c3;<sub>2</sub>R antagonist AC927 (2 &#x003bc;M), and <bold>3c</bold> (employed at 30 and 100 nM), the <bold>5c</bold> precursor compound lacking the HDACi hydroxamic moiety. Results were quantified by the crystal violet assay and spectrophotometry (absorbance, 590 nm). (<bold>b</bold>) Proliferation of CM A375 cells exposed to <bold>5c</bold> (90 nM) alone or in the presence of PTZ (2 &#x003bc;M) or AC927 (2 &#x003bc;M). Hydroxamic-null <bold>3c</bold> was employed at 90 and 200 nM. Results were quantified by acridine orange staining and fluorescence spectroscopy (excitation, 490 nm; emission, 520 nm). Data in (<bold>a</bold>,<bold>b</bold>) are expressed as percentages of the vehicle DMSO control (CTR; indicated as dashed blue lines). *, <italic toggle="yes">p</italic> &#x0003c; 0.05; **, <italic toggle="yes">p</italic> &#x0003c; 0.01; and ***, <italic toggle="yes">p</italic> &#x0003c; 0.001 vs. CTR by Student&#x02019;s <italic toggle="yes">t</italic>-test.</p></caption><graphic xlink:href="pharmaceuticals-18-00179-g003" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00179-f004"><label>Figure 4</label><caption><p>Antiangiogenic effects of the HDAC/&#x003c3;<sub>1</sub>R dual-ligand <bold>5c</bold> in mouse endothelial C166 cells. (<bold>a</bold>) Representative phase-contrast images (magnification, &#x000d7;4) of the capillary tube-like structures formed upon incubation with VEGF-A (VEGF, 80 ng/mL) for 3 h. (<bold>b</bold>) Quantification of vascular network formations with the angiogenesis analyzer tool of the NIH-Image-J (software version 1.51k). Three parameters were measured: total length, total mesh area and number of nodes. Endothelial cells were treated with 30 nM or 5 &#x000b5;M of <bold>5c</bold> and <bold>3c</bold>, or (-)-1, the positive antiangiogenic control (5 &#x000b5;M). Data were normalized to the VEGF-A-stimulated effect over the vehicle (DMSO) control condition (CTR; indicated as dashed blue lines). **, <italic toggle="yes">p</italic> &#x0003c; 0.01 vs. VEGF by one-way ANOVA.</p></caption><graphic xlink:href="pharmaceuticals-18-00179-g004" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00179-f005"><label>Figure 5</label><caption><p>Antiangiogenic signaling by the HDAC/&#x003c3;<sub>1</sub>R dual-ligand <bold>5c</bold> in endothelial C166 cells. (<bold>a</bold>) Representative phase-contrast images (magnification, &#x000d7;4) of vasculature-like organizations promoted by VEGF-A (80 ng/mL; 3 h). (<bold>b</bold>) Angiogenesis was quantified as described in <xref rid="pharmaceuticals-18-00179-f004" ref-type="fig">Figure 4</xref>b, followed by the combination of all three parameters evaluated (lengths, mesh area and nodes; shown in <xref rid="app1-pharmaceuticals-18-00179" ref-type="app">Figure S2</xref>) into a single score (reflecting mean &#x000b1; SEM of the three distinct values, from three independent experiments). Results were expressed as angiogenesis inhibition activity (%), calculated as 100&#x02013;[(A/B) &#x000d7; 100], where A is the value observed in the presence of <bold>5c</bold> or (-)-1 (alone or plus pentazocine/AC927) and B is the correspondent value observed in the VEGF-A condition. Treatments included 5 &#x000b5;M of <bold>5c</bold> or (-)-1, alone or in the presence of pentazocine (PTZ, 2 &#x003bc;M) or AC927 (AC, 2 &#x003bc;M). ***, <italic toggle="yes">p</italic> &#x0003c; 0.001 vs. <bold>5c</bold>; <sup>#</sup>, <italic toggle="yes">p</italic> &#x0003c; 0.05 and <sup>##</sup>, <italic toggle="yes">p</italic> &#x0003c;0.01 vs. (-)-1 by one-way ANOVA.</p></caption><graphic xlink:href="pharmaceuticals-18-00179-g005" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00179-f006"><label>Figure 6</label><caption><p>Inhibition of membrane protrusion formation by the HDAC/&#x003c3;<sub>1</sub>R dual-ligand <bold>5c</bold>. Cell spreading was quantified as the ratio of cells extending membrane protrusions (filopodia and lamellipodia) over the total cell number per microscopic field (magnification, &#x000d7;20) on an inverted microscope, and expressed as the percent of spreading inhibition [<xref rid="B42-pharmaceuticals-18-00179" ref-type="bibr">42</xref>]. In MCF7 cells, dual-ligands were employed at 100 nM each. In all tumor cells, treatments were performed for 1 h. Percent inhibition of cell spreading was calculated with respect to the vehicle (DMSO) control condition (CTR; indicated as a dashed blue line). *, <italic toggle="yes">p</italic> &#x0003c; 0.05 and **, <italic toggle="yes">p</italic> &#x0003c; 0.01 vs. CTR by one-way ANOVA.</p></caption><graphic xlink:href="pharmaceuticals-18-00179-g006" position="float"/></fig><table-wrap position="float" id="pharmaceuticals-18-00179-t001"><object-id pub-id-type="pii">pharmaceuticals-18-00179-t001_Table 1</object-id><label>Table 1</label><caption><p>Ligand binding affinities toward &#x003c3;<sub>1</sub>R and &#x003c3;<sub>2</sub>R. HP, haloperidol; PTZ, pentazocine. Data are means &#x000b1; SD.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Compound</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Ki (nM) &#x000b1; SD</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c3;<sub>1</sub>R</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c3;<sub>2</sub>R</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>5c</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">19.0 &#x000b1; 1.6</td><td align="center" valign="middle" rowspan="1" colspan="1">2051.2 &#x000b1; 737.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<bold>3c</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">28.0 &#x000b1; 4.4</td><td align="center" valign="middle" rowspan="1" colspan="1">1330.0 &#x000b1; 286.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HP</td><td align="center" valign="middle" rowspan="1" colspan="1">2.6 &#x000b1; 0.4</td><td align="center" valign="middle" rowspan="1" colspan="1">77.0 &#x000b1; 18.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PTZ</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.3 &#x000b1; 0.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1465.0 &#x000b1; 224.0</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00179-t002"><object-id pub-id-type="pii">pharmaceuticals-18-00179-t002_Table 2</object-id><label>Table 2</label><caption><p>Antiproliferative IC<sub>50</sub> of <bold>5c</bold> on cancer 92.1, A375, A549, 786-O and T84 cells, and normal MRC-5 and WS1 fibroblasts. Data are expressed as means &#x000b1; SD.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Human Cells</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">5c, IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">92.1 (Uveal Melanoma)</td><td align="center" valign="middle" rowspan="1" colspan="1">24.8 &#x000b1; 5.8</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">A375 (Cutaneous Melanoma, CM)</td><td align="center" valign="middle" rowspan="1" colspan="1">91.5 &#x000b1; 11.4</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">A549 (Lung Carcinoma)</td><td align="center" valign="middle" rowspan="1" colspan="1">118.1 &#x000b1; 13.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">786-O (Renal Adenocarcinoma)</td><td align="center" valign="middle" rowspan="1" colspan="1">150.4 &#x000b1; 24.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">MRC-5 (Normal Skin Fibroblast)</td><td align="center" valign="middle" rowspan="1" colspan="1">156.7 &#x000b1; 55.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">T84 (Colorectal Carcinoma)</td><td align="center" valign="middle" rowspan="1" colspan="1">1198.0 &#x000b1; 380.6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WS1 (Normal Skin Fibroblast)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1162.0 &#x000b1; 186.7</td></tr></tbody></table></table-wrap></sec></back></article>